NATIONAL ADAP MONITORING PROJECT - AIDS United

NATIONAL ADAP MONITORING PROJECT
ANNUAL REPORT
April 2002
Prepared by
Chris Aldridge
Danielle Davis
Arnold Doyle
National Alliance of State and Territorial AIDS Directors
Jennifer Kates
The Henry J. Kaiser Family Foundation
Lei Chou
AIDS Treatment Data Network

The Henry J. Kaiser Family Foundation is an independent, national health philanthropy dedicated to providing
information and analysis on health issues to policymakers, the media, and the general public. The Foundation is not
associated with Kaiser Permanente or Kaiser Industries.

NATIONAL ADAP MONITORING PROJECT
ANNUAL REPORT
April 2002
Prepared by
Chris Aldridge
Danielle Davis
Arnold Doyle
National Alliance of State and Territorial AIDS Directors
Jennifer Kates
The Henry J. Kaiser Family Foundation
Lei Chou
AIDS Treatment Data Network

Acknowledgements
The Henry J. Kaiser Family Foundation, The National Alliance of State and Territorial AIDS Directors (NASTAD)
and the AIDS Treatment Data Network (ATDN) would like to thank the state ADAP and AIDS program managers
and staff for their time and efforts in completing the National ADAP Survey, June 2001, which serves as the
foundation for this report. The authors also wish to thank Murray Penner (NASTAD) and Ardine Hockaday (Kaiser
Family Foundation) for their research and graphic design assistance.
About AIDS Drug Assistance Programs
In 1987, Congress first appropriated funds to assist states in providing the relatively costly drug AZT [the first
antiretroviral approved by the Food and Drug Administration (FDA)] to AIDS patients. State health departments
were directed by Congress to use these AZT Assistance Program funds to purchase and deliver AZT to eligible
individuals. As AIDS treatment options increased and resources allowed, AZT Assistance Programs began to cover
other approved antiretroviral medications and drugs to prevent and treat opportunistic infections. These programs
were incorporated into Title II of the Ryan White CARE Act upon its initial passage in 1990 and became commonly
known as AIDS Drug Assistance Programs (ADAPs).
ADAPs provide FDA approved HIV-related prescription drugs to underinsured and uninsured individuals living with
HIV/AIDS. The CARE Act gives states 1 broad authority to set program eligibility criteria and to decide what HIVrelated
treatments to include on ADAP formularies. For many people with HIV, ADAPs serve as a gateway to a
broad array of healthcare and supportive services funded through the CARE Act and to other sources of coverage
including Medicaid, Medicare, and private insurance. Since 1996, Congress has earmarked funds under Title II of
the CARE Act specifically for ADAPs. Many states also provide state resources to ADAPs. All 50 states, the
District of Columbia, Guam, Puerto Rico, and the Virgin Islands currently operate ADAPs. 2
The National ADAP Monitoring Project
The Henry J. Kaiser Family Foundation (KFF) commissions the National ADAP Monitoring Project, which is
conducted in partnership with the National Alliance of State and Territorial AIDS Directors (NASTAD) and the
AIDS Treatment Data Network (ATDN). The Project seeks to provide timely information on the current status of
state and territorial ADAPs, trends over time, and key issues that impact ADAPs and their ability to provide
medications to people living with HIV/AIDS. The National ADAP Survey, conducted by NASTAD and ATDN,
serves as the basis for the Project’s Annual Report. The survey, sent to all state and territorial ADAP directors,
includes questions on budgets, expenditures, client utilization, client demographics, eligibility criteria, and
formularies from June of each year. The resulting data create a snapshot of ADAPs that can be compared over time.
The Project’s Annual Report is released in the spring of each year.
The National ADAP Monitoring Project Annual Report, 2002
This report represents the sixth annual report released by the National ADAP Monitoring Project and is based on
data from June 2001, unless otherwise indicated. All 54 state and territorial ADAPs responded to the 2001 survey.
Due to differences in data collection among states and territories, some ADAPs do not answer all survey questions.
Where trend data are presented, only states that provided relevant data in all periods are included. Every effort has
been made to ensure that the annual report represents the current status of ADAPs as reported by survey
respondents; however, some data may have changed between collection and this report’s release.
1 The term “state” is used generically in this report to include both states and territories.
2 The Federated states of Micronesia and the Marshall Islands, two Pacific U.S. territories, will receive federal ADAP earmark
funding for the first time in FY 2002.

National ADAP Monitoring Project:
Annual Report
April 2002
TABLE OF CONTENTS
Executive Summary 5
Introduction 5
National ADAP Trends & Key Themes
Detailed Findings from the Current Survey 6
State-by-State Summary ADAP Profile 9
States/Territories with Current or Planned Program Restrictions, February 2002 11
State/Territorial ADAP Coverage of Recommended Drugs to Prevent Opportunistic 12
Infections, 2001
Charts 15
Conclusion 37
Appendices 43
Appendix I: Total Clients Served, Expenditures and Prescriptions Filled
in June 2000 and June 2001
Appendix II: ADAP Expenditures, by Class, June 2001
Appendix III: Prescriptions Filled, by Class, June 2001
Appendix IV: Race/Ethnicity of June 2001 ADAP Clients
Appendix V: Gender and Age of June 2001 ADAP Clients
Appendix VI: Income Level and Insurance Status of June 2001 ADAP Clients
Appendix VII: Health Status of ADAP Clients Enrolled During 12-Month Period, FY 2001
Appendix VIII: ADAP Budget FY 2001: Federal and State Sources
Appendix IX: ADAP Budgets for FY 2000 and FY 2001: Total Federal and State
Appendix X: Major FY 2001 Budget Categories Compared with FY 2000
Appendix XI: ADAP Formularies by State/Territory

Executive Summary

Introduction
Spending on prescription drugs is one of the fastest
growing segments of overall health care spending. 1,2
Spending on HIV-related drugs is no exception.
Combination antiretroviral therapy and medications for
the prevention and treatment of HIV-related
opportunistic infections are critical for HIV-infected
individuals to achieve positive health outcomes. Yet
HIV drugs are expensive, costing between $10,000 and
$12,000 per year. 3 Newer, more expensive drugs and
the use of additional drugs to boost effectiveness or as
“salvage” therapy may drive costs even higher. 4 The
expense of HIV drugs creates a significant barrier for
HIV-positive individuals who do not have access to
private or public insurance or whose insurance does not
sufficiently cover costs associated with prescription
medications. 5 AIDS Drug Assistance Programs
(ADAPs) provide FDA approved HIV-related
prescription drugs to underinsured and uninsured
individuals living with HIV/AIDS in all 50 states, the
District of Columbia, Guam, Puerto Rico, and the
Virgin Islands. 6 As such, ADAPs—estimated to have
served close to 140,000 clients in 2001, 7 including
almost 77,000 clients in the month of June 2001
alone—play a vital role in the healthcare of many HIV
infected individuals.
ADAPs operate within a dynamic environment, amid a
variety of public and private insurance and care
programs that provide prescription medications. Like
all Ryan White CARE Act programs, ADAPs serve as
payer of last resort, when no other safety-net program
can provide the necessary drugs for those infected.
ADAPs are not entitlement programs; annual federal,
and in some cases state, appropriations determine how
many clients ADAPs can serve and the level of services
they can provide. In addition, the CARE Act gives
states broad authority to set program eligibility criteria
and to decide what HIV-related treatments to include on
ADAP formularies, decisions that are often dictated by
the availability of ADAP resources. Finally, health care
system capacity and the availability of other programs
within a given jurisdiction affect the ability of ADAPs
to fill the gaps in prescription drug coverage. As a
result, ADAPs are vulnerable to changes that impact
fiscal priorities and to changes in other healthcare
programs. Indeed, the recent economic downturn has
Executive Summary
5
introduced new budget pressures for states, including
for state Medicaid programs, the largest public payers
of HIV/AIDS care, which in turn could affect demand
on and resources for ADAPs. In addition to fiscal
changes, the HIV-related treatment environment is
increasingly complex, raising new challenges for
ADAPs over time.
National ADAP Trends & Key Themes
The National ADAP Monitoring Project began tracking
state and territorial ADAPs in 1996, at a time of
tremendous change in the treatment of HIV/AIDS. The
introduction of the first protease inhibitors and a move
toward combination therapy at the end of
1995/beginning of 1996 represented a dramatic
technological shift that greatly impacted ADAPs.
Combination therapy became the first therapy to
produce remarkable benefits to those living with
HIV/AIDS, greatly increasing both length and quality
of life. With the promise of new therapies, many people
sought testing and treatment for the first time, causing
ADAP enrollment to jump 23% in the last 6 months of
1996 alone, with some ADAPs experiencing increases
of 50% or more during that period. National ADAP
expenditures increased by 37% during the last six
months of 1996 as well.
To meet this challenge, Congress appropriated
supplemental funding for ADAPs in late 1996, leading
to an increase of 97% ($182 million) in the national
ADAP budget from FY 1996 to FY 1997 alone. Since
that time, national ADAP trends have remained
relatively constant over time, with ADAP client
utilization, expenditures, and budgets growing but at
slower rates, although individual states have
experienced change at different rates.
Analysis of data from 1996 through 2001, collected by
the National ADAP Monitoring Project, highlights
several major trends and key themes over time,
including:
• The demographic makeup of ADAP clients has
remained fairly constant over the past several years.
ADAPs continue to serve primarily people of color—
although whites comprise the single largest
demographic group. Most ADAP clients continue to

e low-income and uninsured, and most are men.
• The number of clients served and the monthly
program expenditures of state and territorial ADAPs
have continued to grow over time, although at slower
rates. Expenditure growth outpaced the growth in
client utilization between 1996 and 2001. During this
period, ADAP client utilization increased by 144%;
ADAP monthly drug expenditures increased by
320%. Growth in the number of clients may reflect
several factors including: increases in the number of
people living with HIV/AIDS; increasing client
demand; and increases in funding for ADAPs,
enabling them to serve more people. Expenditure
growth is attributable to several factors including:
increases in client utilization; rising drug prices; and
the increasing complexity of treatment regimens.
• The national ADAP budget has also continued to
grow over time, although, like clients and
expenditures, at slower rates. Between FY 1996 and
FY 2001, the national ADAP budget increased by
329%. The federal ADAP earmark continues to
represent the core of the national ADAP budget.
Slightly more than two-thirds of states provide state
general revenue funds to their ADAP programs. In
the remaining states, ADAPs must rely solely on
federal funding.
• Despite the overall growth in the national ADAP
budget, access to ADAPs continues to vary greatly
depending upon where one lives, as indicated by wide
variations in income eligibility criteria and formulary
coverage across states, and the continued use of
waiting lists and other access restrictions by some
jurisdictions. Variations in access are the result of
both the availability of other resources—and therefore
the size of the gap that ADAPs are asked to fill—as
well as state discretion over ADAP program design.
• While different states have faced restrictions over
time, a subset repeatedly struggles with lower ADAP
income eligibility, more limited formularies, and
other program restrictions. In at least four of the last
six fiscal years (FY 1996–2001), the following 13
states—primarily southeastern and frontier states—
have capped/limited client enrollment and/or
restricted access to antiretrovirals: Alabama,
Arkansas, Georgia, Idaho, Kentucky, Maine,
Montana, North Carolina, Oklahoma, South Carolina,
South Dakota, Texas, and Wyoming.
6
• Finally, all states take advantage of the most costeffective
drug discount mechanisms available to their
ADAPs—primarily the 340B Drug Discount Program.
Given the rapidly rising costs of prescription drugs,
however, many states are continuing to explore other
options to obtain more significant drug
discounts/rebates on state-purchased pharmaceuticals.
Detailed Findings from the Current
Survey
In addition to these overall themes, findings from the
most recent survey period of June 2001 include:
Clients, Expenditures, and Prescriptions
• The number of clients served by ADAPs grew to
76,743 in June 2001. The overall growth rate for
ADAPs reporting complete client and expenditure
data between 1996 and 2001, the entire period of the
National ADAP Monitoring Project, was 144%,
including a 10% increase over the last year alone, a
rate of growth smaller than in prior periods (see
Charts 1 and 3).
• ADAP drug expenditures grew to almost $64 million
in June 2001. The overall expenditure growth rate for
ADAPs reporting complete client and expenditure
data between 1996 and 2001 was 320%, including a
16% increase in the last year. Antiretrovirals continue
to represent the bulk of drug expenditures (87%) (see
Charts 2, 4, and 6).
• Per capita drug expenditures were $831 in June 2001
(see Chart 5).
• State ADAPs filled a total of 246,062 prescriptions in
June 2001 (see Chart 7).
ADAP Client Demographics
• The demographic makeup of ADAP clients has
remained fairly constant since 1996. The majority of
ADAP clients in June 2001 were people of color, with
African Americans representing approximately onethird
(34%) and Hispanics representing about onequarter
(24%) of the national ADAP population.
Asian/Pacific Islanders and American Indians/Alaska
Natives accounted for less than 1% each. White non-
Hispanics represented 38% of ADAP clients in June
2001 (see Chart 8).
• Eight in ten (80%) ADAP clients in June 2001 were
men, and almost all (99%) ADAP clients were over
the age of 18 (see Chart 9).

• ADAPs continue to serve a low-income population,
with almost 80% of June 2001 ADAP clients
reporting incomes at or below 200% of FPL, 8
including slightly less than half (44%) reporting
incomes less than 100% FPL (see Chart 10).
• The majority of ADAP clients are uninsured. Six
percent of June 2001 ADAP clients were reported to
have Medicaid coverage and 10% percent were
reported to have Medicare coverage (the number of
dually covered among this group is unknown).
Eleven percent of clients were reported to have some
level of private insurance coverage (see Chart 11).
The National ADAP Budget
• The national ADAP budget grew to $810 M in FY
2001, an increase of approximately $86 million over
FY 2000. The national ADAP budget has increased
by 329% since FY 1996, including a 12% increase
since last year, compared to a 9% increase over the
prior reporting period (see Chart 14).
• The core of the national ADAP budget continues to
be federal ADAP funding allocated under Title II of
the Ryan White CARE Act (the ADAP earmark). The
federal ADAP earmark accounted for nearly threequarters
of the national ADAP budget in FY2001 (see
Chart 15).
• Much of the national ADAP budget increase in FY
2001 was due to increases in Title I Eligible
Metropolitan Area (EMA) contributions 9 and state
general revenue funding of ADAP (see Charts 18 and
19). Eight ADAPs received contributions from Title I
EMAs within their jurisdictions compared to 9 in FY
2000, although the dollar amount was higher in FY
2001. Thirty-eight states provided state general
revenue support to ADAPs in FY 2001, compared to
37 in FY 2000 (see Appendix X). Funding from
these sources has been highly variable due to other
factors such as needs within the Title I EMA and state
budget fiscal constraints.
ADAP Restrictions
• Ten states/territories—Alabama, Georgia, Idaho,
Kentucky, Maine, North Carolina, South Dakota,
Texas, Wyoming, and Guam—reported having one or
more program restrictions such as capped enrollment,
limited antiretroviral access, and expenditure caps in
response to fiscal constraints, as of February 2002
(see State-by-State Summary ADAP Profile). All of
these states, except Guam, have reported restrictions
7
in four of the last six fiscal years. 10 The three states
reporting capped or restricted access to antiretroviral
drugs were Maine, Texas and Guam.
• The state ADAPs that consistently report program
restrictions such as limited formularies, low financial
eligibility criteria and/or additional clinical eligibility
criteria, confront unique state level concerns that
prevent ADAP expansion. Common issues include
few state resources to direct toward ADAP, relatively
less generous Medicaid programs and no state
indigent/uninsured care program. In some
jurisdictions, the state legislative body must approve
various aspects of ADAP expansion.
Client Eligibility Criteria and State Formularies
• Financial eligibility for ADAPs ranged from a low of
125% FPL in North Carolina to a high of 500% FPL
or more in Massachusetts, New Jersey, and New
York. In addition to financial eligibility
requirements, seven states reported additional
clinical criteria for clients to access ADAP (e.g.,
specific CD4 or viral load ranges). Some ADAPs
have implemented additional clinical criteria
specifically for access to antiretroviral drugs (see
State-by-State Summary ADAP Profile).
• ADAP formularies ranged from a low of 18 drugs
covered in two states, Louisiana and Utah, to 471
drugs covered in New York. Two state ADAPs,
Massachusetts and New Jersey, moved to an open
formulary 11 since the previous National ADAP
Monitoring Project report (see Appendix XI).
• Almost all state ADAPs cover all FDA-approved
antiretrovirals. South Dakota continues to be the only
ADAP that does not provide coverage for protease
inhibitors due to lack of resources. Coverage of
drugs to prevent and treat opportunistic infections is
increasing, but remains uneven. Ten states currently
offer all 16 highly recommended drugs for the
prevention and treatment of opportunistic infections
according to Public Health Service/Infectious Disease
Society of America (PHS/IDSA) Guidelines, up from
8 last year. 12 A total of 36 states now cover 10 or
more of these recommended OI drugs, up from 31
states last year. Only 2 states do not cover any of the
recommended OI drugs, compared to 4 last year (see
State-by-State Summary ADAP Profile).
Other Issues
Last year’s report identified several issues that could

affect state ADAPs over the coming years, each of
which was assessed by the current survey:
• New antiretroviral treatment guidelines released last
year, suggesting delaying the initiation of antiretroviral
therapy until later in illness. 13 State ADAP programs
reported that this clinical change has yet to have a
significant impact on ADAPs given that ADAP clients
generally enter the program late in disease progression,
with very low CD4 counts, at which point,
antiretroviral therapy would generally be indicated.
• Ryan White CARE Act Amendments of 2001
(reauthorizing the CARE Act). The CARE Act
Amendments contained provisions allowing ADAPs
more flexibility, such as allowing ADAP funds to be
used for medical monitoring and adherence programs.
Many states reported, however, that the demand for
medications prevented them from taking advantage of
this flexibility over the last year. More importantly,
the reauthorized CARE Act also allowed for the
1 Kaiser Family Foundation, Prescription Drug Trends:
A Chartbook Update, November 2001.
2 Steinbrook, R., “The Prescription Drug Problem,” New England
Journal of Medicine, Vol. 346, No. 11, March 2002.
3 Health Resources and Services Administration, The ADAP
Manual: AIDS Drug Assistance Program of the Ryan White
CARE Act, 1999.
4 A regimen used after a person develops resistance to the majority
of available therapies is sometimes referred to as “salvage”
therapy. These therapies often involve four or more drugs.
5 Kaiser Family Foundation, Financing HIV/AIDS Care: A Quilt
with Many Holes, October 2000.
6 The Federated states of Micronesia and the Marshall Islands, two
Pacific U.S. territories, will receive federal ADAP earmark
funding for the first time in FY 2002.
7 Health Resources and Services Administration, ADAP Fact
Sheet. Available: www.hab.hrsa.gov/programs/factsheets/
adap1.htm.
8 In 2001, the FPL was $8,590 per year (slightly higher in Alaska
and Hawaii) for a household of 1.
8
provision of supplemental grants to states with severe
ADAP needs. 14 While this “ADAP supplemental” has
begun to help some states expand their programs and
ease restrictions, a core group of states continues to
have limited or restricted programs. The continued
program restrictions and limitations in these states
may be indicative of less generous Medicaid
programs or lack of other indigent care programs.
The State-by-State ADAP Summary Profile that begins
on the next page provides a synopsis of each ADAPs
eligibility criteria, coverage of specific drug classes,
budget information, client utilization and expenditures,
and reported program limitations/restrictions that were
in place as of February 2002. Maps showing current or
planned program restrictions and coverage of OI drugs
across the country are also presented. These are
followed by charts showing current data and trends over
time. Detailed tables with data by state are contained in
the Appendices.
9 Under the Ryan White CARE Act, an EMA’s Ryan White HIV
Services Planning Council can decide to allocate Title I dollars to
their state ADAP program.
10 This was the first year in which Guam provided data for the
National ADAP Monitoring Project.
11 An open formulary provides access to any FDA-approved HIVrelated
prescription drug.
12 USPHS/IDSA, Guidelines for the Prevention of Opportunistic
Infections in Persons Infected with Human Immunodeficiency
Virus, November 2001. Available: www.hivatis.org/guidelines/
other/OIs/OIGNov27.pdf.
13 Department of Health and Human Services/The Henry J. Kaiser
Family Foundation, Guidelines for the Use of Antiretroviral
Agents in HIV infected Adults and Adolescents, February 2002.
Available: www.hivatis.org/trtgdlns.html#Adult.
14 Three percent of the ADAP earmark is set aside for supplemental
grants to states with severe needs such as low financial
eligibility, program restrictions, or limited formularies. These
grants were first issued in FY 2001.

State-by-State Summary ADAP Profile
9
1 In 2001, the FPL was $8,590 per year (slightly higher in Alaska and Hawaii) for a household of 1.
2 Refers to additional medical criteria to access ADAP such as a specified CD4 count, viral load, or both. All states require individuals to be HIV positive to
access ADAP.
3 Additional medical criteria applies to ARV drug access only.
4 Virginia financial eligibility at 333% FPL for Northern Virginia only.
5 MA and NJ have an open formulary; see formulary for specific exclusions.
6 The following classes of drugs are covered as groups: Antidepressants, Antilipidemia, Bipolar Medications, Oral Analgesics, Oral Antidiabetics, Topical
Steroids.
Bold indicates changes from the 2000 survey reported in the 2001 survey. Italics indicate data from the 2000 survey.
Shaded areas indicate restrictions lifted since 2000 survey.

State-by-State Summary ADAP Profile
10
1 In 2001, the FPL was $8,590 per year (slightly higher in Alaska and Hawaii) for a household of 1.
2 Refers to additional medical criteria to access ADAP such as a specified CD4 count, viral load, or both. All states require individuals to be HIV positive to
access ADAP.
3 Additional medical criteria applies to ARV drug access only.
4 Virginia financial eligibility at 333% FPL for Northern Virginia only.
5 MA and NJ have an open formulary; see formulary for specific exclusions.
6 The following classes of drugs are covered as groups: Antidepressants, Antilipidemia, Bipolar Medications, Oral Analgesics, Oral Antidiabetics, Topical
Steroids.
Bold indicates changes from the 2000 survey reported in the 2001 survey. Italics indicate data from the 2000 survey.
Shaded areas indicate restrictions lifted since 2000 survey.

States/Territories with Current or Planned Program Restrictions,
February 2002
VT NH
ME
WA
ND
MT
MN
NY
MA
OR
WI
ID
SD
CT
MI
WY
PA
NJ
DE
MD
OH
IN
IL
WV
VA
UT
CO
MO
KY
CA
DC
NC
TN
SC
AR
OK OK
AZ
NM
11
MS AL GA
LA
TX
Guam
Upi
Asatdas
Camp Quezon
Ylig
AK
Agana
Camp Bright
HI
Umatac
Agat
Virgin Islands
Puerto Rico
Anegada
Sombrero
State currently has program restrictions in place (as of 2/02).
Tortola
St. Thomas
Virgin Gorda
St. John
St. Martin
St. Barthelemy
Barbuda
St. Croix
St. Eustatius
Loiza Aldea
San Juan
Maguabo
Cayey
Maunabo
Guayama
Quebradillas
Arecibo
Aguadilla
Barceloneta
Bayamon
Centro Puntas
San Sebastian
Corozal
Utuado
Mayaguez
Orocovis
Castaner Comerio
San German
Coamo
Yauco Ponce
Ensenada
Santa Isabel
St. Kitts
Basse-terre
Saint Johns
Nevis
State has current program restrictions and may implement
additional restrictions in FY 02.
Antigua
State has no current restrictions but may implement
restrictions in FY 02.

State/Territorial ADAP Coverage of Recommended Drugs* to
Prevent Opportunistic Infections, 2001
ME
VT NH
WA
NY
ND
MT
MN
MA
OR
WI
ID
SD
CT
MI
WY
PA
NJ
OH
DE
MD
IN
IL
WV
VA
UT
CO
MO
KY
DC
CA
NC
TN
SC
AR
OK OK
AZ
NM
MS AL GA
LA
12
TX
Guam
AK
Upi
Asatdas
Agana
Camp Bright
Camp Quezon
Ylig
Agat
Umatac
Inarajan
HI
Virgin Islands
Puerto Rico
Sombrero Virgin Islands
Anegada
Tortola
St. Thomas
Virgin Gorda
St. John
St. Martin
St. Barthelemy
Loiza Aldea
San Juan
Maguabo
Cayey
Maunabo
Guayama
Barbuda
St. Croix
St. Eustatius
Quebradillas
Arecibo
Barceloneta
Bayamon
Centro Puntas
San Sebastian
Corozal
Utuado
Mayaguez
Orocovis
Castaner Comerio
San German
Coamo
Yauco Ponce
Ensenada
Santa Isabel
All 16 Recommended OI Drugs Covered (11 jurisdictions).
St. Kitts
Basse-terre
Saint Johns
Nevis
Antigua
10 or more Recommended OI Drugs Covered (36 jurisdictions
including those that cover all 16).
Less than 10 OI Drugs Covered (18 jurisdictions).
*IDSA/PHS Highly Recommended Drugs to Prevent Opportunistic Infections in People with HIV

Charts

Chart 1
ADAP Clients Served and Top Ten States, by Clients Served, June 2001
Number Number of Clients
80,000
State/Territory June 2001
70,000
60,000
50,000
40,000
30,000
76,743
1 California
2 Florida
3 New York
4 Texas
13,641
12,987
11,824
5,513
20,000
5 Georgia 3,230
10,000
0
June 2001
Clients
6 New Jersey
7 Puerto Rico
8 Illinois
9 Pennsylvania
2,845
2,798
2,486
2,143
10 Virginia 1,485
Note: Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and the Virgin Islands.
In June 2001, ADAPs served 76,743 clients nationally. Ten states accounted for more than three quarters (77%) of
all clients served in June 2001, with 5 states accounting for 61% of all clients. In general, these states represent
the states with the highest AIDS prevalence (see Appendix I).
15

Chart 2
ADAP Drug Expenditures and Top Ten States, by Expenditures, June 2001
$70,000,000
$60,000,000
$50,000,000
$40,000,000
$30,000,000
$20,000,000
$10,000,000
$0
$63,789,458
June 2001
Expenditures
Note: Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and the Virgin Islands.
State/Territory Expenditures, June 2001
1 California $13,959,151
2 New York $13,530,163
3 Florida $4,837,867
4 Texas $3,791,192
5 New Jersey $2,862,398
6 Georgia $2,637,349
7 Puerto Rico $2,179,291
8 Pennsylvania $1,964,109
9 North Carolina $1,807,633
10 Illinois $1,753,051
National ADAP monthly drug expenditures totaled $63,789,458 in June 2001. As with clients served,
10 states accounted for 77% of June 2001 drug expenditures and 5 states accounted for 61% of drug
expenditures (see Appendix I).
16

Number
80,000
70,000
60,000
50,000
40,000
30,000
20,000
10,000
0
Chart 3
Trends in ADAP Client Utilization, 1996–2001
40%
June–96
22%
June–97
17%
June–98
The National ADAP Monitoring Project has been collecting data from state ADAPs since 1996. A majority of
ADAPs (43) have provided client utilization and expenditure data over this period, and therefore offer an
important window into trends over time. The number of clients served by ADAPs continues to grow over
time, but at a decreasing rate. Between 1996 and 2001, ADAP client utilization increased by 144%,
including a 10% increase in the last year alone. This compares to a 40% increase between 1996 and 1997. Growth
in the number of clients may reflect several factors including: increases in the number of people living with
HIV/AIDS; increasing client demand due to the availability of more effective therapies and/or state ADAP program
client outreach efforts; and increases in funding available to ADAPs, enabling them to serve more people over time.
17
11%
June–99
144%
June–00
10%
June–01
Note: District of Columbia, Georgia, Guam, Louisiana, Missouri, New Mexico, North Dakota, Puerto Rico, Tennessee, Virgin Islands, and Wyoming
not included.

Millions of Dollars
Chart 4
Trends in ADAP Drug Expenditures, 1996–2001
$60
$50
$40
$30
$20
$10
$0
93%
37%
Monthly ADAP drug expenditures have also increased over the past several years and at a faster rate than
client growth. Between 1996 and 2001, expenditures grew by 320%, including a 16% increase in the last
year alone. As with client utilization, the rate of expenditure growth has decreased over time.
Expenditure growth is driven by several factors including: increases in the number of clients served;
rising drug prices; and the increasing complexity of treatment regimens (e.g., moving from 2 to 3, to even 5 or more
drugs used in combination).
18
23% 12%
16%
320%
June–96 June–97 June–98 June–99 June–00 June–01
Note: District of Columbia, Georgia, Guam, Louisiana, Missouri, New Mexico, North Dakota, Puerto Rico, Tennessee, Virgin Islands, and Wyoming
not included.

Note: Guam not included.
OI/All Other
$107
(13%)
Chart 5
Per Capita Spending, June 2001
Total Per Capita Spending= $831
Nationally, in June 2001, ADAPs spent an average of $831 per client served, with about seven out of
every eight dollars being spent on antiretrovirals ($724). The remainder (13% or $107) was spent
per client on all other drugs, including drugs for the prevention and treatment of opportunistic
infections (OIs).
19
ARV
$724
(87%)

Chart 6
ADAP Drug Expenditures, by Class, June 2001
NNRTI
12%
“A1” OI
5%
Note: Connecticut, Guam, Maine, and Massachusetts not included.
OI/All Other
8%
Total = $63,789,458
20
PI
29%
NRTI
46%
In June 2001, fifty states, representing 98% of total ADAP drug expenditures, were able to provide expenditure
data for all drug classes, including the 16 “A1” opportunistic infection drugs recommended by the Infectious
Disease Society of America/Public Health Service. Spending breakdowns were similar to last year’s National
ADAP Monitoring Report. Antiretrovirals continue to account for the bulk of ADAP drug expenditures (87%).
Among the three classes of approved antiretroviral drugs—nucleoside reverse transcriptase inhibitors (NRTIs),
protease inhibitors (PIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs)—NRTIs account for almost
half of ADAP drug expenditures (46%), followed by PIs (29%), and NNRTIs (12%). All other drugs, including
drugs that prevent and treat opportunistic infections, account for 13% of drug spending. The 16 “A1” OI drugs
alone accounted for 5% spent of total drug spending (see Appendix II).
The 16 “A1” drugs as recommended by the Infectious Disease Society of American/Public Health Service,
Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus,
November 2001 include: acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin),
famciclovir (Famvir), fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH),
itraconazole (Sporonox), leucovorin, pyrazinamide, pyrimethamine (Daraprim, Fansidar), rifampin, sulfadiazine, and
TMP/SMX (Bactrim).

Chart 7
ADAP Prescriptions Filled, by Class, June 2001
“A1” OI
11%
OI/All Other
26% NRTI
36%
PI
17%
Total = 246,062
Note: Connecticut, Florida, Georgia, Guam, Maine, and Massachusetts not included.
States filled a total of 246,062 prescriptions in June 2001—up 19% compared to June 2000. Forty-eight
states, representing 92% of total prescriptions filled in June 2001, were able to provide data on prescriptions
filled by class. As with expenditures by class, prescriptions for ARVs represent the majority of all
prescriptions filled (63%), although ARVs represent a smaller proportion of prescriptions filled than of total
drug expenditures (see Chart 6). Prescriptions for all other drugs, including OI drugs, represented 37%, including
11% represented by category “AI” OI drugs. The percentage of prescriptions filled for NRTIs decreased by 3%
compared to June 2000, while the percentage of NNRTIs remained the same (10%). Prescriptions for PIs remained
relatively constant, and the number of OI prescriptions filled increased by 5% (see Appendix III).
21
NNRTI
10%

Chart 8
ADAP Clients, by Race/Ethnicity, June 2001
Asian/PI

Female
21%
Chart 9
ADAP Clients, by Gender and by Age, June 2001
Male
79%
Gender Age
Note: Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and the Virgin Islands.
23
19 Years 99%
The majority of ADAP clients continue to be male and over the age of 19. In June 2001, more than three
quarters (79%) of ADAP clients were male; approximately one-fifth were female (21%)—the same
percentage breakdown as reported in last year’s National ADAP Monitoring Project report. Almost all
ADAP clients were over the age of 19 (99%). Again, there was no marked change from data collected in
previous years, although individual states/territories have varying gender and age client demographics
(see Appendix V).

Unknown
>400% FPL
301–200% FPL
201–300% FPL
101–200% FPL

Private Ins
Medicare
Medicaid
Chart 11
ADAP Clients, by Insurance Status, June 2001
Forty-six jurisdictions, representing 43,087 or 56% of June 2001 ADAP clients, reported data on client
insurance status. The majority of ADAP clients continue to lack private or public insurance. Eleven percent
of ADAP clients served in June 2001 had private insurance, similar to last year’s report (10%). About 6% of
the total were reported to be Medicaid beneficiaries (including individuals in the Medicaid spenddown
process). Approximately 10% of ADAP clients were reported to be Medicare beneficiaries—up 2% compared to
June 2000 ADAP clients. Jurisdictions were not asked to report/estimate the number of dually covered (Medicaid
and Medicare) ADAPs clients (see Appendix VI).
25
6%
10%
11%
0% 2% 4% 6% 8% 10% 12%
Note: California, Colorado, Connecticut, Florida, Illinois, Montana, Oregon, and Puerto Rico not included.
Insurance categories are not mutually exclusive.

Chart 12
Health Status of ADAP Clients Enrolled During 12-Month Period, FY 2001
200–350
17%
>500
21%
351–500
14%
Unknown
6%
ADAP programs were asked to provide the disease status at the time of enrollment for the population of
clients who enrolled in ADAP over a recent 12-month period. Twenty-five jurisdictions were able to
provide these data, representing 29,219 ADAP clients (42% of the June 2001 utilizing population). The
majority of states reported data collected between May 2000 and September 2001 except Kansas,
Oklahoma, and Vermont (see Appendix VII). In addition, a number of states require annual re-enrollment for ADAP
clients. As a result, figures do not necessarily reflect new clients exclusively.
More than four in ten (42%) ADAP clients have a CD4 count below 200, an AIDS diagnosis, or symptomatic HIV
infection—suggesting that a significant number of ADAP clients continue to enroll well into disease progression.
One fifth (21%) of clients have a CD4 count above 500.
For purposes of the 2001 Survey, health status was defined by the following categories:
• AIDS (ever diagnosed)—clients that have an AIDS diagnosis regardless of current CD4 count or being currently
asymptomatic.
• CD4 200)—clients who may currently be experiencing symptoms but have
not met the criteria for an AIDS diagnosis.
• CD4 200–350 (not AIDS nor symptomatic HIV)—clients whose CD4 count is within this range and is not symptomatic
nor has an AIDS diagnosis.**
• CD4 351–500 (not AIDS nor symptomatic HIV)—client whose CD4 count is within this range and is not symptomatic nor
has an AIDS diagnosis.**
• CD4 >500 (not AIDS nor symptomatic HIV)—client whose CD4 count is above 500 and is not symptomatic nor has an
AIDS diagnosis.
26
AIDS
Diagnosed
19%
200)
5%
Note: see Appendix VII for list of states/territories that provided data on ADAP client health status.
*Because CD4 counts can fluctuate rapidly on HAART, some physicians may not diagnose a client with AIDS although their CD4 count is below 200,
meeting a CDC criteria for an AIDS diagnosis.
**The current Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV Infected Adults and Adolescents
recommend that treatment with antiretrovirals may be delayed, in some cases, until a person’s CD4 count is at or below 350. These guidelines, and
consultation with ADAP Directors, determined the current ranges specified on the 2001 survey.

Chart 13
State Coverage of Resistance Testing,* FY 2001
No
65%
27
Yes
35%
The 19 states are: Alaska, California, Connecticut, Delaware, Florida, Georgia, Louisiana, Maryland, Massachusetts, Montana, New York, Ohio
Oregon, South Carolina, South Dakota, Tennessee, Virginia, Washington, and the Virgin Islands.
*Resistance testing can show whether a person’s virus is likely to be suppressed by each anti-HIV drug. There are two different types of resistance
tests: Genotypic tests look for genetic mutations that have been linked to drug resistance; Phenotypic tests assess how much of a drug is required
to block viral activity.
For the first time, jurisdictions were asked if their state/territorial AIDS program—the entity in state health
departments that manages all state-level HIV/AIDS prevention and care programs, including ADAPs—
provided funding (federal or state) to cover genotypic and phenotypic testing.* As genotypic and
phenotypic testing become more integrated into practice, ADAPs and other programs that serve uninsured
and underinsured individuals with HIV must determine how to pay for them. Nineteen states (35%) reported that
their state AIDS program provides funding for resistance testing. Of the 19 states, 15 reported covering both
genotypic and phenotypic, and 4 reported covering genotypic testing only (Georgia, Tennesse, Washington, and
the Virgin Islands). These data, however, may provide an incomplete picture of statewide coverage for resistance
testing, since individuals may also access resistance-testing services through agencies/programs funded primarily
through other components of the Ryan White CARE Act (e.g., Titles I and III).

Millions of Dollars
Milions of Dollars
$900
$800
$700
$600
$500
$400
$300
$200
$100
$0
$188.5
Chart 14
The National ADAP Budget, FY 1996–2001
$370.8
$510.0
28
$665.5
$724.5
$810.2
1996 1997 1998 1999 2000 2001
National ADAP Budget, Rate of Growth in Dollars and Percent, FY 1996–2001
$200
$180
$160
$140
$120
$100
$80
$60
$40
$20
$0
$182.3
97%
$139.2
38%
$155.5
30%
$59.0
9%
$85.7
12%
96–97 97–98 98–99 99–00 00–01
Note: Bars on the National ADAP Budget Rate of Growth graph represent changes between the two years indicated, not aggregate changes
since FY 1996.
The national ADAP budget grew to over $810 million in FY 2001, up from $188.5 million in FY 1996,
representing a 329% increase. The ADAP budget represents combined funding from the Ryan White
CARE Act (ADAP earmark, Title I, Title II and ADAP supplemental), state funding, and other federal
funding (e.g., carry over from prior years).
In general, the national ADAP budget has been increasing but at a decreasing rate (similar to trends in client and
expenditure growth). Between FY 1996 and FY 1997, for example, the budget increased by 97% ($182.3 million)
compared to a 12% (or $85.7 million) increase between FY 2000 and FY 2001. For the first time over this period,
however, the ADAP budget between FY 2000 and FY 2001 increased at a slightly greater rate than in the prior
period (12% or $85.7 million compared to 9% or $59.0 million). Increases in funding from state sources and Title
I EMAs drove much of the overall budget increase in FY 2001.
120%
100%
80%
60%
40%
20%
0%

ADAP Supplemental
$17,674,990
2%
Chart 15
National ADAP Budget, by Source, FY 2001
Other Federal
$17,617,447
2%
Title I
$24,679,377
3%
The federal ADAP earmark accounted for the largest proportion of the FY 2001 national ADAP budget,
representing $571.3M or 71% of the total (compared to 73% in FY 2000). State contributions
represented the second greatest budget category ($149.6M or 18%), similar to FY 2001. Funding from
Title I EMAs increased to $24.7M or 3% of the budget, up only slightly from FY 2000 (2%), while
contributions from the Title II base declined slightly as a percentage of the budget, from 5% in FY 2000 to 4%
in FY 2001 ($29.3M). Funding from other federal sources represented $17.6M or 2% of the FY 2001 budget.
The slight variations in proportional representation of budget categories reflect both the introduction of the
ADAP supplemental and actual dollar changes in some categories.
FY 2001 was the first year for the ADAP supplemental grants authorized by the Ryan White Care Act
Amendments of 2000 (which reauthorized the CARE Act). Three percent of ADAP earmark funds ($17.7
million in FY 2001) appropriated by Congress were set aside for grants to states with severe needs as indicated
by such factors as financial eligibility set at or below 200% FPL, limited formularies, or program restrictions.
Fourteen states received supplemental grants in FY 2001. Combined ADAP earmark and supplemental funding
represents 73% of the national ADAP budget, the same proportion as the earmark in FY 2000, before the
introduction of the ADAP supplemental.
Most jurisdictions saw an increase in their overall ADAP budget between FY 2000 and FY 2001, although 6
states experienced decreases (see Appendix VIII).
29
Earmark
$571,330,000
71%
Title II Base
$29,264,897
4%
State
$149,635,427
18%

Millions in Dollars
Millions in Dollars
$600
$500
$400
$300
$200
$100
$0
$51.9
Chart 16
The ADAP Earmark, FY 1996–2001
$167.0
$285.5
30
$460.6
$527.6
$571.3
1996 1997 1998 1999 2000 2001
The ADAP Earmark, Rate of Growth in Dollars and Percent, FY 1996–2001
$200
$180
$160
$140
$120
$100
$80
$60
$40
$20
$0
222%
$115.1
$118.5
71%
$175.1
61%
$67.0
15%
$43.7
8%
96–97 97–98 98–99 99–00 00–01
250%
200%
150%
100%
Note: Bars on the ADAP Earmark Rate of Growth graph represent changes between the two years indicated, not aggregate changes since FY 1996.
The ADAP earmark represents money set aside in Title II of the CARE Act specifically to fund ADAPs. The
ADAP earmark—the largest component of the national ADAP budget—grew to $571.3 million in FY 2001,
representing a more than ten-fold increase since FY 1996, when the earmark totaled $51.9 million; most of
the rate of growth occurred between FY 1996 and 1997. The rate of growth in the ADAP earmark has slowed
over time—the earmark increased by 222% between FY 1996 and 1997 compared to a 15% increase between FY
1999 and 2000 and an 8% increase between FY 2000 and 2001.
Twenty-two states indicated they planned to use a total of about $15 million in federal ADAP earmark dollars to fund
insurance maintenance programs (approximately 3% of the total ADAP earmark). Thirteen states noted their plans
to use federal ADAP earmark funds for medical monitoring, adherence and outreach programs, but did not report
total dollars amount.
The ADAP supplemental grants, first implemented in FY 2001, served as one reason for the earmark decline, since
money was set aside from the earmark for supplemental grants. Combining earmark and supplemental funds results
in an increase of $61.4 million or 11% over last year. Over time, the federal ADAP earmark (including FY 2001
supplemental grant funding) has come to represent the core of the national ADAP budget, growing from 27% of the
budget in FY 1996 to 73% in FY 2001.
50%
0%

Millions in Dollars
$80
$70
$60
$50
$40
$30
$20
$10
$0
$50.1
Chart 17
Title II Base Funding, FY 1996–2001
$67.6
$71.9
31
$50.5
$38.6
$29.3
1996 1997 1998 1999 2000 2001
Title II Base Contributions, Rate of Growth, in Dollars and Percent, FY 1996–2001
Millions in Dollarss
$20
$15
$10
$5
$0
-$5
-$10
-$15
-$20
-$25
$17.5
35%
$4.3
6%
-30%
-$21.4
-24%
-$11.9
-$9.3
-24%
96–97 97–98 98–99 99–00 00–01
40%
30%
20%
10%
0%
-10%
-20%
-30%
-40%
Note: Bars on the Title II Base Contributions Rate of Growth graph represent changes between the two years indicated, not aggregate changes since
FY 1996.
States can choose to use some of their Ryan White Title II Base funds for their ADAPs. Title II Base
contributions to ADAPs have largely decreased over time. Contributions from the Title II Base decreased
between FY 1996 and FY 2001 overall ($50.1 million compared to $29.3 million, a more than 40%
decrease). Title II Base contributions decreased by 24% ($9.3 million) between FY 2000 and FY 2001, the
same percentage decrease as between FY 1999 and FY 2000 (24% or $11.9 million). Title II Base funds for ADAPs
represented only 4% of the national budget in FY 2001, compared to 27% in FY 1996. As noted previously by the
National ADAP Monitoring Project, one reason for this continued decline may be that states have more flexibility
with base funds to support other non-ADAP services such as primary care, mental health care, substance abuse
treatment, and supportive services. In FY 2001, twenty-four states allocated Title II base funds to ADAP, up from 23
in FY 2000 (see Appendix X).

Millions in Dollars
Millions in Dollars
$30
$25
$20
$15
$10
$5
$0
$25.9
Chart 18
Title I EMA Funding, FY 1996–2001
$24.3
$26.8
32
$23.2
$17.5
$24.7
1996 1997 1998 1999 2000 2001
Title I EMA Funding, Growth Rate, in Dollars and Percent, FY 1996–2001
$8
$6
$4
$2
$0
-$2
-$4
-$6
-$8
$2.5
41%
$7.2
-$1.6 10%
-$3.6
-6%
-$5.7
-13%
96–97 97–98 98–99
-25%
99–00 00–01
Note: Bars on the Title 1 EMA Funding Rate of Growth graph represent changes between the two years indicated, not aggregate changes
since FY 1996.
50%
40%
30%
20%
10%
0%
-10%
-20%
-30%
Contributions to ADAP from Title I EMAs increased by 41% between FY 2000 and FY 2001, to reach a total
of $24.7 million. This reverses the trend of falling Title I contributions, both in actual dollars and percent
growth, since FY 1998. Title I contributions now make up 3% of the ADAP budget, up from 2% last year.
While states make decisions regarding allocation of state general revenue funds and Title II base funds, Ryan
White HIV Services Planning Councils make allocation decisions regarding Title I funds. Contributions from Title I
funds must be spent to purchase medications for clients living within the Title I EMA. Twenty-seven states and
Puerto Rico have a Title I EMA or a portion of a Tile I EMA in their jurisdiction. The District of Columbia is also a
Title I EMA and includes portions of Maryland and Virginia. Eight ADAPs received contributions from Title I
EMAs in FY 2001 compared to 9 in FY 2000 (see Appendix X).

Millions of Dollars
Millions of Dollars
$160
$140
$120
$100
$80
$60
$40
$20
$0
$50.4
Chart 19
State Funding, FY 1996–2001
$117.4
$119.4
33
$125.5
$128.8
$149.6
1996 1997 1998 1999 2000 2001
State Funding, Rate of Growth, in Dollars and Percent, FY 1996–2001
$80
$70
$60
$50
$40
$30
$20
$10
$0
133%
$67.0
$20.8
$2.0 $6.1 $3.3
16%
2% 5% 3%
96–97 97–98 98–99 99–00 00–01
140%
120%
100%
Note: Bars on the State Funding Rate of Growth graph represent changes between the two years indicated, not aggregate changes since FY 1996.
States can decide to allocate state general revenue funds to their ADAPs. State funding of ADAP increased by
16% between FY 2000 and FY 2001 to reach a total of $149.6 million. The national ADAP budget now
consists of 18% state funding, consistent with FY 2000. Thirty-eight states contributed general revenue
funds to ADAP in FY 2001, up from 37 in FY 2000 (see Appendix X).
80%
60%
40%
20%
0%

Chart 20
ADAP Cost Recovery Resources, FY 2001
Insurance
Recovery
15%
Total = $4.1M
Cost recovery represents reimbursement to ADAPs from other entities for medications purchased through the
ADAP program. Overall, cost recovery represents $4.1 million to ADAPs. Drug rebates, including those
that are voluntary, mandated by state law, or available to ADAPs as 340B entities, continue to make up the
largest percent of ADAP cost recovery (80%). This does not include 340B discounts offered to direct
purchase ADAPs, which are received at the time of purchase. Another recovery source continues to be insurance
recovery (15%), where the ADAP receives reimbursement from insurance providers for medications purchased for
their clients. Insurance providers include both private providers and public providers such as Medicaid.
Miscellaneous recovery (5%) includes income received from various sources such as private contributions and
corporate donations.
34
Miscellaneous
5%
Drug Rebates
80%

Conclusion

Serving almost 77,000 largely uninsured and low-income
people with HIV/AIDS in June 2001, state and territorial
ADAPs continue to play a critical role in the provision of
medications to those who are uninsured and
underinsured. ADAPs fill the gaps in prescription drug
coverage and often serve as a bridge to comprehensive
health care resources including other Ryan White-funded
programs, Medicaid, and private insurance. After a
major shock to the system in late 1995—with the
introduction of protease inhibitors and combination
therapy as the standard of care—trends in ADAP client,
expenditure, and budget growth have remained relatively
constant, as all three continue to grow but at slower rates.
National ADAP budget growth, however, has not
eliminated program restrictions and limitations in some
states, and some states have experienced large
fluctuations in client utilization, expenditures, and
budgets over time. In addition, as discretionary
programs that rely mainly on annual federal—and in
some cases, state—appropriations, ADAPs’ continuing
fiscal stability is subject to changes in federal and state
political, economic, and social priorities. ADAPs often
cannot predict whether they will face budget shortfalls
until well into their fiscal year.
While these overall trends are expected to continue,
there are several factors and issues on the horizon that
could affect the ability of ADAPs to meet increasing
client demand over time. These factors include:
The Fiscal Outlook
• The Office of Management and Budget (OMB) is
predicting a federal deficit that will reach over $106
billion in FY 2002 and over $80 billion in FY 2003. 1,2
This economic downturn has had a dramatic impact
on states. The National Association of State Budget
Officers (NASBO) and the National Governors
Association (NGA) report that total state deficits
reached $40 billion in FY 2001. 3 Statutes in many
states prohibit deficit spending, forcing these states to
enact drastic budget cuts. At the same time, the costs
involved in strengthening the public health system’s
bioterrorism preparedness have become the focus of
attention. Budget deficits and a focus on
bioterrorism at both the federal and state level have
already resulted in resource constraints.
Conclusion
37
• For the second year, President Bush has
recommended flat funding for certain federal
HIV/AIDS programs in his FY 2003 proposed
budget, including the ADAP program. Last year,
ADAP programs fared well during Congressional
appropriations. Final appropriations for FY 2003 are
not yet known. With federal dollars accounting for
the core of the national ADAP budget, some states
could be forced to further restrict access to ADAP
programs.
• The continuing increases in the price of medications
coincide with federal and state fiscal concerns. The
price of prescription drugs increased more than three
times the rate of inflation between 1998 and 2000. 4
While the federal drug discount program (the 340B
Program) used by most ADAPs largely shields them
from annual price increases greater than inflation, a
drug company that has not increased prices for two or
more quarters may include past inflationary increases
in a single quarter increase. 5 This recently occurred
in the case of Sustiva, a popular non-nucleoside
reverse transcriptase inhibitor (NNRTI) used in many
protease-sparing regimens, whose price to ADAPs
rose by 10%. 6 Such a sudden increase makes it more
difficult for ADAPs to budget effectively.
The Treatment/Technological
Outlook
• T-20, the first fusion inhibitor, could receive FDA
approval prior to the end of 2002, marking the first
dramatic technological change in HIV treatment since
the introduction of protease inhibitors. 7 Initial data on
this drug indicate that it is highly effective, particularly
when treating patients who have developed multiple
drug resistance to the current drug classes. Beyond
2002, other fusion inhibitors besides T-20 will likely
receive approval, in addition to another new class of
drugs, integrase inhibitors, and new generations of
existing classes, creating further shifts in highly active
antiretroviral therapy (HAART). 8 The impact of these
changes on ADAP client utilization and drug
expenditures remains unclear.
• Structured intermittent therapy (SIT), consisting of
defined periods on and then off treatment designed to
ease the effects of HAART and potentially increase

adherence, is another shift. Initial studies indicate
some promise to this strategy. 9 The impact it may
have on ADAP remains uncertain. SIT could
potentially create cost savings, as clients no longer
use medications on a continuous basis.
• Another concern facing ADAPs is the impact of
hepatitis C co-infection. Up to 25% of HIV infected
individuals are co-infected with HCV, the virus that
causes the symptoms of hepatitis C. 10 State and local
health department resources and infrastructure to test
for and treat HCV vary greatly among states. The
cost of HCV treatment for co-infected individuals
will likely fall to ADAPs since few HCV specific
treatment programs exist at the federal or state level.
ADAPs must also continue to make decisions
regarding medications that treat the side effects of
HAART, including adding statins that reduce
cholesterol, blood pressure medications, and diabetes
medications. All of these could lead to an increase in
1 Office of Management and Budget, Historical Tables, Budget of
the United States Government, Fiscal Year 2003, 2002. Available:
www.whitehouse.gov/omb/budget/fy2003/budget.html.
2 The federal fiscal year runs from October 1st through September
30th. The ADAP fiscal year runs from April 1st through March
31st. State fiscal years will vary by state. Fiscal years referred
to in this report are ADAP fiscal years unless otherwise noted.
3 The National Governors Association and The National
Association of State Budget Officers (2001) The Fiscal Survey of
States, 2001. Available: www.nasbo.org/Publications/
fiscsurv/fiscsurvdec2001.pdf.
4 Kaiser Family Foundation, Prescription Drug Trends:
A Chartbook Update, November 2001.
5 For more information on the ADAP drug discount programs, see:
Kaiser Family Foundation and the National Alliance of State and
Territorial AIDS Directors, AIDS Drug Assistance Programs:
Getting the Best Price, April 2002.
6 Red Book, Thomson Medical Economics, 2001.
38
the cost to ADAPs of maintaining individuals on
HAART.
• Finally, drug resistance and resistance testing present
ongoing challenges. As genotypic and phenotypic
testing 11 become more integrated into practice,
ADAPs and other programs that serve uninsured and
underinsured individuals with HIV must determine
how to pay for them. Drug resistance presents
another challenge in itself; as individuals become
more resistant to medications it becomes more likely
they will be on “salvage” therapy—regimens
consisting of four or more drugs and sometimes more
than one protease inhibitor to boost effectiveness.
These factors have cost implications for ADAPs.
ADAPs have always operated as part of a dynamic
health care treatment and financing environment, subject
to changes in both. The National ADAP Monitoring
Project will continue to monitor the status of ADAPs
and the factors identified above over the next year.
7 Unlike current antiretrovirals, fusion inhibitors work to prevent
HIV from entering a CD4 cell.
8 Integrase inhibitors interfere with the enzyme integrase that
assists HIV in binding its genetic material with that of the CD4
cell.
9 Altfeld, M, Dybul, M, Miller, V, “An STI Confab: Insights Into
Treatment Interruptions for Patients with Early, Chronic, and
Drug Resistance HIV Disease,” Physicians Research
Network/PRN Notebook, September 2001. Available:
www.prn.org/prn_nb_cntnt/vol6/num3/sti_frm.htm.
10 Centers for Disease Control and Prevention, Frequently Asked
Questions About Co-infections with HIV and Hepatitis C, August
2001.
11 Resistance testing can show whether a person’s virus is likely to
be suppressed by each anti-HIV drug. There are two different
types of resistance tests: Genotypic tests look for genetic
mutations that have been linked to drug resistance; Phenotypic
tests assess how much of a drug is required to block viral activity.

Appendices

Appendix I
Total Clients Served, Expenditures and Prescriptions
Filled in June 2000 and June 2001

Total Clients Served, Expenditures and Prescriptions Filled in June 2000 and June 2001
43
NR indicates data not reported. NA indicates calculation not possible due to missing data.
NC indicates not covered on ADAP formulary.
National Comparison Totals are calculated based on those states that reported complete data in all three categories
in both time periods.

Total Clients Served, Expenditures and Prescriptions Filled in June 2000 and June 2001
45
NR indicates data not reported. NA indicates calculation not possible due to missing data.
NC indicates not covered on ADAP formulary.
National Comparison Totals are calculated based on those states that reported complete data in all three categories
in both time periods.

Appendix II
ADAP Expenditures, By Class, June 2001

ADAP Expenditures, By Class, June 2001
49
R indicates data not reported. NA indicates calculation not possible due to missing data.
NC indicates not covered on ADAP formulary.
National Comparison Totals are calculated on those states that provided complete expenditure data for all classes.

ADAP Expenditures, By Class, June 2001
50
NR indicates data not reported. NA indicates calculation not possible due to missing data.
NC indicates not covered on ADAP formulary.
1 2 Expenditures for A1 OI drugs reported with OI/All Other drugs for MA. MT covers a limited number of OI drugs but
had no expenditures in June 2001.
National Comparison Totals are calculated on those states that provided complete expenditure data for all classes.

Appendix III
Prescriptions Filled, by Class, June 2001

Prescriptions Filled, by Class, June 2001
53
NR indicates data not reported. NA indicates calculation not possible due to missing data.
NC indicates not covered on ADAP formulary.
National Comparison Totals are calculated on those states that provided prescription breakout data. 2MT ADAP
covers a limited number of OI drugs but did not purchase any in June 2001.

Prescriptions Filled, by Class, June 2001
54
NR indicates data not reported. NA indicates calculation not possible due to missing data.
NC indicates not covered on ADAP formulary.
1Expenditures for A1 OI drugs reported with OI/All Other drugs for MA and ME.
National Comparison Totals are calculated on those states that provided prescription breakout data. 2MT ADAP
covers a limited number of OI drugs but did not purchase any in June 2001.

Appendix IV
Race/Ethnicity of June 2001 ADAP Clients

Race/Ethnicity of June 2001 ADAP Clients
57

Appendix V
Gender and Age of June 2001 ADAP Clients

Gender and Age of June 2001 ADAP Clients
61

Appendix VI
Income Level and Insurance Status of June 2001
ADAP Clients

Income Level and Insurance Status of June 2001 ADAP Clients
65
A number of states were unable to provide data for all categories. These states are not included in the total
percentage calculations.

Income Level and Insurance Status of June 2001 ADAP Clients
66
A number of states were unable to provide data for all categories. These states are not included in the total
percentage calculations.

Appendix VII
Health Status of ADAP Clients Enrolled During
12-Month Period, FY 2001

Health Status of ADAP Clients Enrolled During 12-Month Period, FY 2001
69
Data collected between 5/00–9/01, except Kansas (1/00–12/00), Oklahoma (4/01–9/01), and Vermont (10/00–8/01).
Some states requires annual re-enrollment, therefore chart does not reflect new clients exclusively. Some states
unable to provide this data.

Appendix VIII
ADAP Budget FY 2001: Federal and State Sources

ADAP Budget FY 2001: Federal and State Sources
73

ADAP Budget FY 2001: Federal and State Sources
74

Appendix IX
ADAP Budgets for FY 2000 and FY 2001:
Total Federal and State

ADAP Budgets for FY 2000 and FY 2001: Total Federal and State
NR indicates data not reported. NA indicates calculation not possible due to
missing data. NC indicates not covered on ADAP formulary.
National Comparison Totals are calculated on those states that provided complete
data in both time periods.
77

Appendix X
Major FY 2001 Budget Categories
Compared with FY 2000

Major FY 2001 Budget Categories Compared with FY 2000
81

Major FY 2001 Budget Categories Compared with FY 2000
ADAP Supplemental Grants were first awarded in FY 2001 and are therefore not included in
this comparison. The "Other Federal" budget category, which includes carryover, varies
greatly by state according to the states budgeting process and is therefore not included in this
comparison.
82

Appendix XI
ADAP Formularies by State/Territory

Alabama
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), fluconazol (Difulcan), ganciclovir (Cytovene), lecovorin, sulfatrim DS (Bactrim, Septra).
Other OIs- epoetin alfa (Procrit), dapsone, valganciclovir (Valcyte). Hepatitis C- none.
Alaska
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporonox), leucovorin, pyrazinamide,
pyrimethamine (Daraprim, Fansidar), rifampim, sulfadiazine, TMP/SMX (Bactrim) Other OIs- amphotericin B, atovaquone,
ciprofloxacin, clindamycin, clotrimazole (Mycelex), dapsone, ethambutol, fomivirsen, ketoconazole, nystatin, pentamidine
(aerolsolized), pyridoxine, rifabutin. Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Hyperlipidemia- atorvastatin calcium (Lipitor), gemfibrozil (Lopid), pravastatin sodium (Pravachol). Wasting- testosterone
(depotest, patches and gel, oxandrin, deca-durabolin, or delatestry).
ALL OTHERS
diphenox/atr sulf (Lomotil), gabapentin (Neurontin), hepatitis A Vaccine (2 doses), hepatitis B Vaccine (3 doses), influenza
(annually), loperamide (Imodium), pneumococcal Vaccine, prochlorperazine (Compazine), varicella zoster immune globulin.
Arizona
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir, azithromycin (Zithromax), clarithromycin (Biaxin), pyrimethamine (Daraprim), TMP/SMX (Bactrim).
Other OIs- dapsone, pentamidine (NebuPent), rifabutin (Mycobutin), trimethoprim. Hepatitis C- none.
Arkansas
New drugs added since June 2000 indicated in bold.
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), famciclovir (Famvir), fluconazole (Diflucan),
itraconazole (Sporonox), leucovorin, pyrimethamine (Daraprim), sulfadiazine, TMP/SMX (Bactrim, Septra).
Other OIs- amoxicillin/clavulanate (Augmentin), atovaquone (Mepron), cephalexin (Keflex), ciprofloxacin (Cipro), clindamycin
(Cleocin), clofazimine (Lamprene), clotrimazole (Mycelex), dapsone, doxycycline, erythromycin, ethambutol (Myambutol), griseofulvin
(Fulvicin), ketoconazole (Nizoral), metronidazole, nystatin, ofloxacin (Floxin), paromomycin (Humatin), terbenafine (Lamisil),
valacyclovir (Valtrex). Hepatitis C- none.

California
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx ,Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (generic), itraconazole (Sporonox), leucovorin calcium
(Wellcovorin), pyrazinamide (generic), pyrimethamine (Daraprim), rifampim (generic), sulfadiazine (oral generic), TMP/SMX (Bactrim,
Septra). Other OIs- albendazole (Albenza), amikacin sulphate (generic injection), amoxicillin trihydrate (oral generic), amphotericin B
(Fungizone), atovaquone (Mepron), bleomycin sulfate (Blenoxane), ciprofloxacin (Cipro), clindamycin (Cleocin), clofazimine
(Lamprene), clotrimazole (Lotrimin, Mycelex), cyclophosphamide (Cytoxan), dapsone (Avlosulfon), dexamethasone (Decadron),
doxorubicin (Adriamycin), epoetin alpha (Procrit), ethambutol (Myambutol), filgrastim (Neupogen), flucytosine (5FC, Ancobon),
fomivirsen (Vitravene), ketoconazole (Nizoral), isoniazid/rifampin (generic), liposomal duanorubicin (DaunoXome), methotrexate (oral,
injection), metronidazole (oral generic), nystatin (Mycostatin), paclitaxel (Taxol), paromomycin (Humatin), pentamidine (Nebupent,
Pentam), prednisone (oral generic), rifabutin (Mycobutin), trimethoprim (Trimpex, Proloprim), trimetrexate glucuronate (NeuTrexin),
valacyclovir (Valtrex), vinblastine sulfate (Velban), vincristine sulfate (Oncovin). Hepatitis C- interferon alfacon 1 (Infergen), interferon
A-2A (Intron-A, Roferon-A), ribavirin (generic), ribavirin/interferon alpha 2B (Rebetron).
TREATMENTS FOR METABOLIC DISORDERS
Diabetic- glipizide (Glucotrol), rosiglitazone maleate (Avandia). Hyperlipidemia- atorvastatin (Lipitor), gemfibrozil (generic only),
pravastatin (Pravachol), simvastatin (Zocor). Wasting- dronabinol (Marinol), megestrol acetate (Megace), nandrolone (Durabolin,
Deca-Duranbolin), oxandrolone (Oxandrin), somatropin (Serostim), testosterone (generic injection, transdermal).
ALL OTHERS
alitretinoin gel (Panretin Gel), alprazolam (Xanax), amitriptyline hydrochloride (generic), bupropion HCL (Wellbutrin), buspiron HCL
(BuSpar), cephalexin (oral generic), citalopram hydrobromide (Celexa), codeine w/wo ASA, APAP (oral generic), desipramine HCL
(oral generic), dicloxacillin sodium (oral generic), diphenoxylate HCL (Lomotil), divalproex sodium (Depakote), doxycycline hyclate
(oral generic), erythromycin (oral generic), famotidine (generic), fenoprofen calcium (oral generic), fentanyl (Duragesic, hospice clients
only), fluoxetine HCL (Prozac), gabapentin (Neurontin), hepatitis A vaccine, hepatitis B vaccine, hydrocodone w/wo APAP
(oral generic), ibuprofen-prescription strength (generic), imiquimod (Aldara), indomethacin (oral generic), ketoprofen (oral generic),
ketorolac tromethamine (Toradol injection), lamotrigine (Lamictal), lansoprazole (Prevacid), levorphenol tartrate (Levo-Dromoran),
loperamide HCL (generic), lorazepam (oral generic), methadone HCL (oral generic), metoclopramide (Reglan, Clopra), minocycline
HCL (oral generic), morphine sulfate (oral generic), naproxen (oral generic), nefazodone HCL (Serzone), neomycin sulfate (oral
generic), nortriptyline HCL (oral generic), olanzapine (Zyprexa), omeprazole (Prilosec), opium, tincture of, oxycodone w/wo ASA,
APAP (oral generic), pancrelipase (Ultrase), paroxetine HCL (Paxil), penicillin V potassium (oral generic), pneumococcal vaccine
(Pneumovax, Pnu-Immune), probenecid (generic), prochlorperazine (Compazine), promethazine (Phenergan), quetiapine fumarate
(Seroquel), ranitidine HCL (prescription strength generic), risperidone (Risperdal), sertraline (Zoloft), sulindac (oral generic),
tetracycline HCL (oral generic), trazodone HCL (oral generic), vancomycin HCL (oral generic), venlafaxine HCL (Effexor).
Colorado
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), itraconazole (Sporonox), pyrimethamine (Daraprim), sulfadiazine,
TMP/SMX (Bactrim,Septra). Other OIs- amphotericin (Fungizone), atovaquone (Mepron),
clindamycin (Cleocin), clotrimazole (Mycelex), dapsone, ethambutol (Myambutol), pentamidine (Nebupent), rifabutin
(Mycobutin), valacyclovir (Valtrex), valganciclovir (Valcyte). Hepatitis C- none.

Connecticut
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin, clarithromycin (Biaxin), fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir
(Cytovene), itraconazole (Sporonox), leucovorin, pyrimethamine, sulfadiazine, TMP/SMX (Bactrim). Other OIs- amphotericin B
(Fungizone B), atovaquone (Mepron), ciprofloxacin (Cipro), clindamycin (Cleocin), clotrimazole (Lotrimin, Mycelex), dapsone,
erythropoietin (Epogen, Procrit), ethambutol (Myambutol), filgrastim (G-CSF, Neupogen), ketoconazole (Nizoral), metronidazole
(Flagyl), nystatin, ofloxacin (Floxin), paromomycin (Humatin), pentamidine (Pentam 30, NebuPent), prednisone, primaquine, rifabutin
(Mycobutin), terconazole (Terazol 3 & 7), trimethoprim (Proloprim), valcyclovir (Valtrex), valganciclovir (Valcyte).
Hepatitis C- peg-interferon alfa-2b (PEG-Intron), ribavirin (Rebetol).
TREATMENTS FOR METABOLIC DISORDERS
Cardiac- atenolol (Tenormin), diltiazem HCL (Cardizem), hydrochlorothiazide (HCTZ), isosorbide mononitrate (Imdur), lisinopril
(Prinivil, Zestril), nitroglycerin. Diabetic- glipizide (Glucotrol), insulin NPH, insulin regular. Hyperlipidemia- atorvastatin (Lipitor),
fenofibrate (Tricor), gemfibrozil (Lopid), pravastatin (Pravachol). Wasting- dronabinol (Marinol), megestrol acetate (Megace),
nandrolone deconoate (Deca-Duranbolin), oxandrolone (Oxandrin), oxymetholone (Anadrol-50), testosterone (Androgel),
testosterone (Androderm), testosterone cypionate (Depo-Testosterone).
ALL OTHERS
alprazolam (Xanax), amitriptyline (Elavil), amoxicillin, amoxicillin/Pot. Clavulante (Augmentin), cefuroxime, cephalexin, chlorhexidine
gluconate (Peridex), citalopram hydrobromide (Celexa), codeine phosphate/acetominophen, Comvax, dicloxacillin, diphenoxylate
HCL (Lomotil, Lonox), doxycycline, Engerix-B, fentanyl patch (Duragesic), gabapentin (Neurontin), guaifenesin/pseudoephedrine
(Entex PSE), Havrix, hydrocortisone (cream/lotion/ointment), hydroxyzine HCL (Atarax), lactic acid, lithium (Eskalith),
loperamide HCL (Imodium), lorazepam (Generics only), monetasone furoate monohydrate (Nasonex),
olanzapine (Zyprexa), oxycodone HCL controlled release (Oxycontin), paroxetine HCL (Paxil), pneumococcal vaccine,
prochloparazine (Compazine), Recombivax HB, sertraline (Zoloft), triamcinolone (acetonide cream/ointment), Twinrix,
vancomycin, Vaqta, venlaxifine HCL (Effexor).

Delaware
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporonox), leucovorin (Wellcovorin),
pyrazinamide, pyrimethamine (Daraprim), rifampim, sulfadiazine (Microsulfon), TMP/SMX (Bactrim, Septra).
Other OIs- atovaquone (Mepron), ciprofloxacin (Cipro), clindamycin (Cleocin), clotrimazole (Mycelex), clotrimazole vaginal
(Gyne-Lortimin), dapsone (Avo-Sulfon), epoetin alfa (Procrit, Epo), ethambutol (Myambutol), filgrastim (Neupogen), ketoconazole
(Nizoral), miconazole cream (Monistat), ofloxacin (Floxin), paromomycin (Humatin), pentamidine (Nebupent), prednisone (Deltasone),
rifabutin (Mycobutin). Hepatitis C- interferon alfa-2a (Roferon A), interferon alfa-2b (Intron A), interferon alfacon-1 (Infergen),
interferon alfa-2b + ribavirin (Rebetron), peg-interferon alfa-2b (PEG-Intron), ribavirin (Rebetol).
TREATMENTS FOR METABOLIC DISORDERS
Cardiac- isoproterenol (Isuprel), temazepam (Restoril). Diabetic- acarbose (Precose), clorpropamide (Diabinese), glimepiride
(Amaryl), glipizide (Glucotrol), glyburide (Diabeta, Micronase), insulin (all types), metformin (Glucophage), pioglitazone (Actos),
repaglinide (Prandin), rosiglitazone (Avandia), tolazamide (Tolinase), tolbutamide (Orinase).
Hyperlipidemia- atorvastatin (Lipitor), fenofibrate (Tricor), gemfibrozil (Lopid), pravastatin (Pravachol). Wasting- cyproheptadine
(Periactin), dronabinol (Marinol), megestrol acetate (Megace), testosterone replacement products (All types), thalidomide (Thalid).
ALL OTHERS
albuterol inhaler (Ventolin), albuterol/ipratropium (Combivent), alprazolam (Xanax), amitriptyline (Elavil), amoxapine (Asendin),
amoxicillin (Amoxil, Polymox, Trimox), amoxicillin/pot. clavulante (Augmentin), ampicillin (Omnipen, Principen),
beclomethasone (Beclovent, Vanceril), budesonide (Pulmicort), buproprion (Zyban, Wellbutrin), cefixime (Suprax), cefuroxime
(Ceftin), cephalexin (Keflex, Biocef, Keftab), chlordiazepoxide (Librium), citalopram hydrobromide (Celexa), clomipramine
(Anafranil), clorazepate (Tranxene), desipramine (Norpramin), diazepam (Valium), dicloxacillin (Dycil, Dynapen, Pathocill), doxepin
(Sinequan), doxycycline (Doxy, Doxychel, Monodox, Vibramycin), estazolam (Prosom), flunisolide (Aerobid), fluoxetine
(Prozac), flurazepam (Dalmane), fluticasone (Flovent), fluvoxamine (Luvox), gabapentin (Neurontin), imipramine (Tofranil),
ipratropium (Atrovent), lamotrigine (Lamictal), levofloxacin (Levaquin), lithium (Eskalith, Lithobid), loperamide HCL (Imodium),
lorazepam (Ativan), maprotiline (Ludiomil), metaproterenol (Alupent), mirtazapine (Remeron), nefazodone (Serzone), nicotene
replacement products - all forms, nortriptyline (Aventyl, Pamelor), olanzapine (Zyprexa), oxazepam (Serax), paroxetine HCL
(Paxil), penicillin (Pen Vee K, Veetids, Beepen-VK, V-Cillin K), pirbuterol (Maxair), prochloparazine (Compazine), protriptyline
(Vivactil), pyridoxine (Vitamine B-6), salmeterol (Serevent), sertraline (Zoloft), terbutaline (Brethine, Brethaire), trazodone
(Desyrel), triazolam (Halcion), triamcinolone (Azmacort), trimipramine (Surmontil), venlaxifine HCL (Effexor).

Distric of Columbia
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), fluconazole (Diflucan),
ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporonox), pyrazinamide, pyrimethamine (Daraprim), rifampim, sulfadiazine,
TMP/SMX (Bactrim). Other OIs- amphotericin B (Fungizone), atovaquone (Mepron), ciprofloxacin (Cipro), clindamycin (Cleocin),
clotrimazole (Lotrimin, Mycelex), dapsone, doxorubicin (Doxil), ethambutol (Myambutol), ketoconazole (Nizoral), ofloxacin (Floxin),
pentamidine (NebuPent), rifabutin (Mycobutin), valacyclovir (Valtrex). Hepatitis C- interferon alpha.
TREATMENTS FOR METABOLIC DISORDERS
Diabetic- Metformin, glipizide (Glucotrol XL). Hyperlipidemia- atorvastatin (Lipitor). Wasting- dronabinol (Marinol), megestrol
acetate (Megace), oxandrolone (Oxandrin).
ALL OTHERS
acetomenaphine with codeine (Tylenol III and Tylenol IV), amoxicillin/clavulanate (Augmentin), dephenoxylate and atropine (Lomotil),
fentanyl patch (Duragesic), fluoxetine HCL (Prozac), hydrocortisone cream 1%, ibuprofen (800mg), morphine sulfate (MS Contin),
sertraline HCL (Zoloft).
Florida
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), itraconazole
(Sporonox), leucovorin (Folinic Acid), pyrimethamine (Daraprim), TMP/SMX (Bactrim, Septra). Other OIs- atovaquone (Mepron),
dapsone (DDS), erythropoietin (Epogen, Procrit), ethambutol (Myambutol), filgrastim (Neupogen), miconazole (Monistat), rifabutin
(Mycobutin), terconazole (Terazol). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Diabetic- glipizide (Glucotrol), glyburide (Micronase, Glynase, Diabeta), metformin (Glucophage). Hyperlipidemia- atorvastatin
(Lipitor), gemfibrozil (Lopid), pravastatin (Pravachol). Wasting- megestrol (Megace), nandrolone (Deca-Durabolin), oxandrolone
(Oxandrin), testosterone cypionate.
ALL OTHERS
amitriptyline (Elavil), diphenoxylate (Lomotil), gabapentin (Neurontin), hepatitis A Vaccine (Havrix), hepatitis B Vaccine (Engerix B),
lamotrigine (Lamictal), nortriptyline (Pamelor), pneumococcal vaccine (Pneumovax), procholorperazine (Compazine).
Georgia
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC ), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), ganciclovir (Cytovene),
isoniazid (INH), itraconazole (Sporonox), leucovorin (Wellcovorin), pyrazinamide, pyrimethamine (Daraprim), rifampim (Rifadin), sulfadiazine,
TMP/SMX (Bactrim). Other OIs- atovaquone (Mepron), clindamycin (Cleocin), clotrimazole (Mycelex troches), dapsone
(Avlosulfon), erythropoietin (Epogen, Procrit), ethambutol (Myambutol), flucytosine (Ancobon), gabapentin (Neurontin), ketoconazole
(Nizoral), loperamide (Imodium), nystatin (Mycostatin / Nilstat), prednisone (Deltasone), primaquine, prochlorperazine (Compazine),
rifabutin (Mycobutin), trimethoprim (TimpexProlorim). Hepatitis C- none.

Guam
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir). PIs- amprenavir
(Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir (Fortovase).
NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), itraconazole (Sporonox), leucovorin, pyrimethamine
(Daraprim), TMP/SMX (Bactrim). Other OIs- atovaquone (Mepron), cephalexin (Keflex), ciprofloxicin (Cipro), clinamycin,
clotrimazole (Mycelex), dapsone, erythropoietin (Procrit), filgrastim (Neupogen, G-CSF), ketoconazole (Nizoral), pentamidine
(Nebupent), rifabutin (Mycobutin). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Wasting- megestrol acetate (Megace).
ALL OTHERS
aliretinoin (Panretin), fluoxetine (Prozac), hydrocortisone cream.
Hawaii
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporonox), leucovorin,
pyrazinamide, pyrimethamine (Daraprim), rifampim (Rifadin), sulfadiazine, TMP/SMX (Septra). Other OIs- amphotericin B,
atovaquone (Mepron), ciprofloxacin (Cipro), clindamycin, clofazimine (Lamprene), clotrimazole (Mycelex), dapsone, daunorubicin
(DaunoXome), epoetin alfa (Procrit), ethambutol (Myambutol), filgrastim (Neupogen), ketoconazole (Nizoral), metronidazole (Flagyl),
nystatin, paclitaxel (Taxol), paromomycin (Humatin), pentamidine (NebuPent), prochlorperazine (Compazine), rifabutin (Mycobutin),
terbinafine (Lamisil), valacyclovir (Valtrex), valgancyclovir (Valcyte). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Diabetic- glyburide, metformin (Glucophage), tetracycline. Hyperlipidemia- atorvastatin (Lipitor), fenofibrate (Tricor),
gemfibrozil (Lopid), niaspan, pravastatin (Pravachol). Wasting- megestrol acetate (Megace), nandrolone decanoate
(Deca-Durabolin), oxandrolone (Oxandrin), testosterone cypionate (DepoTest), testosterone (AndroGel).
ALL OTHERS
alitretinoin (Panretin Gel), bupropion (Wellbutrin), cephalexin (Keflex), citalopram (Celexa), diclosacillin, diphenoxylate HCI
(Lomotil), doxycycline, erythromycin (ERY-TAB), fluoxetine (Prozac), gabapentin (Neurontin), hydrocortisone cream, imiquimod
(Aldara cream), loperamide (Imodium), mirtazapine (Remeron), mupirocin (Bactroban), pancrelipase (Ultrase), paroxetine (Paxil),
phisohex, sertraline (zoloft), venlafaxine hydrochloride (Effexor).
Idaho
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- TMP/SMX (Bactrim). Other OIs- dapsone. Hepatitis C- none.

Illinois
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporonox), leucovorin (Folinic
Acid), pyrazinamide, pyrimethamine (Daraprim), rifampim (Rifadin, Rimactane, Rifater), sulfadiazine, TMP/SMX (Bactrim,
C0-Trimoxazole, Septra, Sulfatrim). Other OIs- amphotericin B (Fungizone), atovaquone (Mepron), ciprofloxacin (Cipro), clindamycin
HCL (Cleocin HCL), clindamycin phosphate (Cleocin Phosphate), clindamycin palmitate (Cleocin pediatirc), clotrimazole (Lotrimin,
Mycelex), dapsone (DDS), ethambutol (Myambutol), ketoconazole (Nizoral), miconazole (Monistat), nystatin (Mycostatin), ofloxacin
(Floxin), paromomycin sulfate (Humatin), pentamidine (Nebupent, Pentam), primaquine phosphate, rifabutin (Mycobutin), streptomycin
sulfate, sulfamethoxazole (Gantanol, Urobak), terconazole (Terazol 3, 7), trimethoprim (TMP, Proloprim, Trimpex).
Hepatitis C- interferon alpha-2b (Intron A).
TREATMENTS FOR METABOLIC DISORDERS
Wasting- dronabinol (Marinol), megestrol acetate (Megace).
ADAP FORMULARIES
ALL OTHERS
amoxicillin (Amoxil, Trimox, Wymox), cefixime (Suprax), cephalexin monohydrate (Keflex), chlorhexidine gluconate (Peridex,
PerioGard), danazol (Danocrine), dicloxacillin sodium (Dycill, Dynapen, Pathocil), doxycycline (Doryx, Vibramycin, Vibra-Tabs), erythromycin
ethylsuccinate (E.E.S.), penicillin VK, tetracycline (Achromycin V, Sumycin, Tetracyn).
Indiana
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), famciclovir (Famvir), fluconazole (Diflucan),
ganciclovir (Cytovene), itraconazole (Sporonox), leucovorin, TMP/SMX (Bactrim, Septra). Other OIs- amphotericin B (Ancobon),
atovaquone (Mepron), clotrimazole (Gyne-Lotrimum, Mycelex), dapsone, flucytosine, ketoconazole (Nizoral), metronidazole (Flagyl),
nystatin (Mycostatin), pentamidine (NebuPent, Pentam), rifabutin (Mycobutin). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Wasting- Testosterone.
ALL OTHERS
acetaminophen + codeine (Tylenol #3, Tylenol + codeine), amantadine (Symmetrel), amitriptyline (Elavil), bromocriptine,
bupropion (Wellbutrin), buspirone (BuSpar), chlorhexidine gluconate (Peridex), clonidine hydrochloride (ApoClonidine,
Catapress, Nu-Clonidine), carbamazepine (Tegretol), desipramine (Norpramine, Pertofrane), diphenhydramine (Benadryl),
diphenoxylate atropine (Lomotil), disulfiram (Antabuse), fluoxetine (Prozac), hydroxyzine (Vistaril, Atarax), klonopin
(Clonazepam), levo-alpha-acetyl-methadol (LAAM),lithium carbonate, methadone (Dolophine, Methadone), morphine sulfate
(Oramorph analgesic patches), naloxone (Narcan), naltrexone (ReVia), nefazodone (Serzone), paroxetine (Paxil), phenobarbital
(Solfoton), phenytoin (Dilantin), povidone-iodine (Betadine), prochlorperazine (Compazine), propranolol (Inderal), sertraline
(Zoloft), sodium valproate (Depakote), tramadol hydrochloride (Ultrarn), trazodone (Desyreo), tricyclic antidepressants
(Sinequan, Tofranil), venlafaxine (Effexor).

Iowa
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), itraconazole
(Sporonox), TMP/SMX (Bactrim, Septra). Other OIs- atovaquone (Mepron), clotrimazole (Mycelex), dapsone, ethambutol
(Myambutol), ketoconazole (Nizoral), nystatin (Mycostatin), pentamidine (Pentam), rifabutin (Mycobutin). Hepatitis C- none.
Kansas
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax),clarithromycin (Biaxin), famciclovir (Famvir), fluconazole (Diflucan),
ganciclovir (Cytovene), itraconazole (Sporonox), TMP/SMX (Bactrim, Septra). Other OIs- atovaquone (Mepron), clindamycin
(Cleocin), clotrimazole (Mycelex), dapsone, ethambutol (Myambutol), ketoconazole (Nizoral), Metronidazole (Flagyl), nystatin
(Mycostatin), paromomycin (Humatin), pentamidine (Nebupent), rifabutin (Mycobutin). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Wasting- dronabinol (Marinol), megestrol acetate (Megace), oxandrolone (Oxandrin).
ALL OTHERS
amitriptyline, cephalexin (Keflex), cephalexin hydrochloride (Keftab), clonazepam (Klonopin), trazodone (Desyrel).
Kentucky
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), leucovorin
(Wellcovorin), TMP/SMX (Bactrim, Septra). Other OIs- ciprofloxacin (Cipro), clindamycin (Cleocin), clotrimazole (Mycelex), dapsone,
ethambutol (Myambutol), ketoconazole (Nizoral), nystatin (Mycostatin), primaquine, rifabutin (Mycobutin). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Wasting- megestrol acetate (Megace).
ALL OTHERS
prenatal vitamins.
Louisiana
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).

Maine
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporonox), leucovorin,
pyrazinamide, pyrimethamine (Daraprim, Fansidar), rifampim, sulfadiazine, TMP/SMX (Bactrim). Other OIs- ciprofloxacin (Cipro),
dapsone, ethambutol (Myambutol), pentamidine (Nebupent). Hepatitis C- none.
Maryland
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (Nydrazid, Rifamate), itraconazole (Sporonox),
leucovorin, pyrazinamide, pyrimethamine (Daraprim, Fansidar), rifampim (Rifadin, Rimactane), sulfadiazine, TMP/SMX (Bactrim).
Other OIs- amphotericin B (Fungisone), atovaquone (Mepron), ciprofloxacin (Cipro,Ciloxan), clindamycin (Cleocin), clotrimazole
(Lotrimin, Mycelex), dapsone, daunorubicin citrate liposomal (DaunoXome), ethambutol (Myambutol), epoetin alpha (Epogen, Procrit),
filgrastim (Neupogen), fomivirsen (Vitravene), ketoconazole (Nizoral), miconazole (Monistat), nystatin (Mycostatin), paromomycin
(Humatin), pentamidine (Pentam, Nebupent), rifabutin (Mycobutin), valacyclovir (Valtrex).
Hepatitis C- interferon alpha-2A (Roferon-A, Intron-A).
TREATMENTS FOR METABOLIC DISORDERS
Hyperlipidemia- atorvastatin (Lipitor), pravastatin (Pravachol). Wasting- megestrol acetate (Megace), nandrolone, oxandrolone
(Oxandrin), testosterone (injection and patches), thalidomide (Thalomid).
ALL OTHERS
amitriptyline (Elavil), buproprion (Wellbutrin, Zyban), citalopran HBr (Celexa), clotrimazole/betamethasone (Lotrisone Cream),
diphenoxylate-atropine (Lomotil), divalproex (Depakote, Depakene), fluoxetine (Prozac), fluphenazine (Prolixin), gabapentin
(Neurontin), haldoperidol (Haldol), hydroxizine (Atarax), imiquimod (Aldara), loperamide (Imodium), nortriptyline (Aventlyl,
Pamelor), octreotide (Sandostatin), olanzapine (Zyprexa), oxymetholone (Anadrol-50), paroxetine (Paxil), prochlorperazine
(Compazine), risperidone (Risperdal), sertraline (Zoloft), trazadone (Desyrel/Desyrel Dividose).
Massachusetts
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporonox), leucovorin,
pyrazinamide, pyrimethamine (Daraprim, Fansidar), rifampim, sulfadiazine, TMP/SMX (Bactrim). Hepatitis C- all FDA approved drugs.
ALL OTHERS
Open Formulary - All FDA approved drugs are covered except the following:
Specific open formulary exclusions: antirheumatic injectables (e.g. Enbrel), botulinum toxin (e.g. botox, mylobloc) compounded
medications for infusion, active medication containing more than one ingredient, gonadotropin, finasteride (Propecia), hyaluronic acid
derivatives (e.g. Hyalgan, Synvisc), immune globulin intravenous IGIV (e.g. sandoglobulin, Venoglobulin), injectable muscle relaxants
(e.g. Lioresal), mifepristone, minoxidil (Rogaine), monoclonal antibodies (e.g. Remicade, Synagis), propoxyphene, recombinant human
growth hormone HGH (e.g. Geref, Humatrop), Viagra.
Class Exculsions:fertility drugs, fluorides, herbal medicaitons, immunizing biologicals, iron, less than effective drugs, nutritional
supplements, over the counter mediations exceptions:(Acetaminophen, Imodium and Metamucil), sex-reassignment drugs, smoking
cessaton drugs, vitamins and minerals.

Michigan
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), itraconazole (Sporonox), leucovorin, pyrimethamine, sulfadiazine,
TMP/SMX (Bactrim, Cotrim, Septra). Other OIs- amphotericin B (Fungizone), atovaquone (Mepron), ciprofloxacin (Cipro),
clindamycin, clotrimazole (Mycelex), dapsone, ethambutol (Myambutol), formivirsen (Vitravene), ketoconazole (Nizoral), ofloxacin
(Ocuflox), pentamidine (Nebupent, Pentam), primaquine, rifabutin (Mycobutin), valacyclovir (Valtrex). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Cardiac- enalapril (Vasotec), furosemide (Lasix), hydrochlorothyazide, nifedipine (Procardia), quinapril (Accupril).
Diabetic- insulin/syringes, metformin (Glucophage). Hyperlipidemia- atorvastatin (Lipitor), fenofibrate (Tricor), gemfibrozil (Lopid).
Wasting- megestrol acetate (Megace), testosterone (Testoderm, Delatestryl, Androderm).
ALL OTHERS
albuterol (Airet, Proventil, Ventolin, Volmax), alprazolam (Xanax), amitriptyline (Elavil), bupropion (Wellbutrin, Zyban),
buspirone (Buspar), cetrizine (Zyrtec), diphenoxylate (Lomotil), doxycycline (Monodox), erythromycin, famotidine (Pepcid),
fexofenadine (Allegra), fluoxetine (Prozac), gabapentin (Neurontin), hepatitis A Vaccine, hepatitis B Vaccine, influenza Vaccine,
lansoprazole (Prevacid), laratadine-pseudoephedrine (Claritin), levofloxacin (Levaquin), loperamide (Imodium), lorazepam (Ativan),
nicotine (Nicotrol, Habitrol, NTC), omeprazole (Prilosec), paroxetine (Paxil), pneumococcal Vaccine (Pneumovax), prochlorperazine
(Compazine), rimantadine (Flumadine), Respirgard II (Nebulizer), setraline (Zoloft), trimethobenzamide (Tigan), zolpidem
(Ambien).
Minnesota
ANTIRETROVIRALS
NRTIs- abacavir/lamivudine/zidovudine (Trizivir), lamivudine (Epivir, 3TC), lamivudine/zidovudine (Combivir), stavudine
(d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir). PIs- lopinavir/ritonavir (Kaletra), nelfinavir
(Viracept), ritonavir (Norvir), saquinavir (Invirase). NnRTIs- nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), fluconazole (Diflucan),
ganciclovir (Cytovene), itraconazole (Sporonox), leucovorin (Wellcovorin), pyrazinamide, pyrimethamine (Daraprim),
rifampim/isonazid (Rifadin, Rifamate), sulfadiazine, TMP/SMX (Bactrim, Septra). Other OIs- albendazole (Albenza), amphotericin B
(Fungizone), atovaquone (Mepron), ciprofloxacin (Cipro), clindanycin (Cleocin), clotrimazole (Lotrimin, Mycelex), dapsone,
econazole (Spectazole), ethambutol (Myambutol), ketoconazole (Nizoral), metronidazole (Flagyl ,Metrogel), miconazole (Micatin,
Moniatat, Zeasorb-AF), nystatin (Mycostatin), ofloxacin (Ocuflox), paromonycin (Humatin), pentamidine (Nebupent, Pentam),
primaquine, rifabutin (Mycobutin), silver sulfadiazine (Thermazene SSD), terconazole (Terazol 7), Valacyclovir (Valtrex),
Valgancyclovir (Valcyte). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Hyperlipidemia- atrovostatin (Lipitor), cholestyramine (Questran), fenofibrate (Tricor), fulvastatin (Lescol), gemfibrozil (Lopid),
niacin (Niaspan), pravastatin (Pravachol), simvastatin (Zocor).
ALL OTHERS
amoxicillin, amoxicillin/culvulanate (Augmentin), bacitracin, bacitracin/polymyxinB, bacitracin Zinc, carbamazepine (Tegretol),
cefadroxil (Duricef), cefazolin (Ancef), cephalexin (Keflex), chlor-hexidine (Peridex), colfazamine (Lamprene), desipramine
(Norpramin, Petrofane), dicloxacillin, divalproex (Depakote), doxepin (Sinequan), doxycycline (Vibramycin), erythromycin (EES),
erythromycin/ethanol, fluoxetine (Prozac), fluvoxamine (Luvox), gabapentin (Neurontin), gentamicin, imipramine (Tofranil),
lamotrigine (Lamictal), levofloxacin (Levaquin), magnesium sulfate, maprotiline (Ludiomil), minocycline (Minocin), mirtazapine
(Remeron), nefazodone (Serzone), neomycin, nitrofurantoin (Macrodantin), nortriptyline (Aventyl, Pamelor), paroxetine (Paxil), penicillin
V Potassium (Vestids), phenelzine (Nardil), phenytoin (Dilantin), primidone (Mysoline), probenecid, protriptyline (Vivactil),
sertraline (Zoloft), tetracycline, tranylcypromine (Pamate), trazodone (Desyrel, Trialodine), trimipramine (Surmontil), tobramycin,
vancomycin, valporic acid (Depkene), venlafxine (Effexor).

Mississippi
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), ganciclovir (Cytovene),
itraconazole (Sporonox), pyrimethamine (Daraprim), sulfadiazine, TMP/SMX (Bactrim). Other OIs- clotrimazole (Mycelex), dapsone,
ethambutol (Myambutol), pentamidine. Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Hyperlipidemia- atorvastatin (Lipitor), niacin. Wasting- oxandrolone (Oxandrin).
ALL OTHERS
amitriptyline (Elavil), gabapentin (Neurontin), sertraline (Zoloft).
Missouri
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir, azithromycin, clarithromycin, famciclovir, fluconazole, ganciclovir, isoniazid, itraconazole, leucovorin,
pyrimethamine, rifampim, sulfadiazine, TMP/SMX. Other OIs- atovaquone, ciprofloxacin, clindamycin, clofazimine, clotrimazole,
dapsone, econazole, ethambutol, griseofulvin, ketoconazole, miconazole, nystatin, ofloxacin, paromomycin, pentamidine, primaquine,
rifabutin, terbinafine, terconazole, valacyclovir, valganciclovir. Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Cardiac- acebutolol, amiloride, amlodipine, atenolol, benazepril, captopril, cardizem, chlorothiazide, chlorthalidone, clonidine, diltiazem,
doxazosin mesylate, enalapril, fosinopril, furosemide, hydrochlorothiazide, irbesartan, labetalol, lisinopril, methyldopa, metoprolol,
nifedipine, nisoldipine, prazosin, propranolol, quinapril, ramipril, spironolactone, terazosin, triamterene, verapamil. Diabetic- acarbose,
chlorpropamide, gilmepiride, glipizide, glyburide, insulin, metformin, miglitol, pioglitazone, rosiglitazone, tolazamide, tolbutamide.
Hyperlipidemia- atorvastatin, cholestyramine, clofibrate, colestipol, fenofibrate, fluvastatin, gemfibrozil, lovastatin, niacin, pravastatin,
simvastatin. Wasting- cyproheptadine, dronabinol, megestrol acetate, nandrolone, oxandrolone, oxymetholone, testosterone.
ALL OTHERS
acetaminophen /codine, albuterol inhaler, alprazolam, amitriptyline, amoxicillin trihydrate, amoxicillin & clavulanate potassium,
ampicillin, baclofen, beclomethasone, benzoropine, betamethasone, bupropion, buspirone, carbamazepine, carbidopa, carisoprodol,
cefaclor, cefadroxil, cefdinir, cefprozil, cefixime, ceftibutin, cefuroxime, clecoxib, cephalexin, cetirizine, chlordiazepoxide, chlorpromazine,
chlorzoxazone, cimetidine, citalopram, clemastine, clobetasol, clomipramine, clonazepam, codeine, cromolyn, cyclobenzaprine,
desipramine, desoximetasone, dexamethasone, diazepam, diclofenac, dicloxacillin, dicyclomine, diflunisal, diphenhydramine,
diphenoxylate, divalproex sodium, dolasetron, doxepin, doxycycline, erythromycin, etodolac, famotidine, fenoprofen, fentanyl,
fexofenadine, flucytosine, flunisolide, fluocinolone, fluocinonide, fluoxetine, flurazepam, fluticasone, fluvoxamine, furazolidone
(Furoxone), gabapentin, granisetron, halcionoide, haloperido, hepatitis A vaccine, hepatitis B vaccine, hydrocodone, hydrocortisone,
hydromorphone, hydroxyzine, ibuprofen (prescription strength), imipramine, indomethacin, ipratropium, ketoprofen, ketorolac,
lamotrigine, lansoprazole, levofloxacin, lithium, loperamide, loracarbef, loratadine, lorazepam, meclizine, meperidine, mepivacaine,
metaxalone, methadone, methocarbamol, metoclopramide, metronidazole, minocycline, mirtazapine, mometasone, montelukast,
morphine immediate release, mupirocin, naproxen, nefazodone, nitrofurantoin, nizatidine, nortriptyline, olanzapine, omeprazole,
ondansetron, orphenadrine, oxaprozin, oxazepam, oxycodone combinations, pancrelipase, paroxetine, penicillin, phenytoin, pirbuterol,
piroxicam, prednisone, primidone, prochlorperazine, promethazine, propoxyphene combinations, ranitidine, risperidone, rofecoxib,
salmeterol, sertraline, sparfloxacin, sucralfate, sulindac, temazepam, terbutaline, tetracycline, theophylline, thiothixene, timolol, tolmetin,
tramadol, trazodone, triamcinolone, trifluoperazine, trimethobenzamide, trovafloxacin, valporic acid, vancomycin, venlafaxine, zolpidem.

Montana
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), foscarnet
(Foscavir), ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporonox), leucovorin (floinic acid), pyrazinamide (Rifater),
pyrimethamine (Daraprim, Fansidar), rifampim (If not covered by County Health), sulfadiazine, TMP/SMX (Bactrim). Other
OIs- amphotericin B (standard formulation only), atovaquone (Mepron), dapsone, ethambutol hydrochloride (Myambutol),
rifabutin (Mycobutin), clotrimazole oral (Mycolex Troches), nystatin (Mycostatin), pentamidine (NebuPent/Pentam), Valacyclovir
(Valtrex ). Hepatitis C- none.
Nebraska
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), famciclovir (Famvir), fluconazole (Diflucan),
isoniazid (Laniazid), itraconazole (Sporonox), pyrazinamide, rifampim (Rifadin), TMP/SMX (Bactrim, Septra). Other OIs- atovaquone
(Mepron), ciprofloxacin (Cipro), clindamycin (Cleocin), clofazimine (Lamprene), clotrimazole (Mycelex), dapsone, ethambutol
(Myambutol), ketoconazole (Nizoral), nystatin (Mycostatin), metronidazole (Flagyl), pentamidine (Pentam), rifabutin (Mycobutin),
valacyclovir (Valtrex). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Wasting- megestroll acetate (Megace).
ALL OTHERS
alprazolam (Xanax), amitriptyline (Elavil), buspirone (BuSpar), bupropion (Weflbutrin), carbamazepine (Tegretol), chlordiazepoxide
(Librium), chlorpromazine (Thorazine), citalopram (Celexa), clomipramine (Anafrabil), clonazepam (Klonopin), clorazepate (Tranxene),
clozapine (Clozaril), desipramine (Norpramin), diazepam (Valium), doxepin (Sinequan), droperidol (Inapsine), estazolam (Prosom),
fluoxetine (Prozac), fluphenazine (Prolixin), flurazepam (Dalmane), fluvoxamine (Luvox), halazepam (Paxipam), haloperidol (Haldol),
hydroxyzine (Atarax, Vistaril), imipramine (Tofranil), lithium (Lithobid), lorazepam (Ativan), loxapine (Loxitane), mesoridazine
(Serentil), mirtazipine (Remeron), molindone (Moban), nefazodone (Serzone), nortriptyline (Pamelor), olanzapine (Zyprexa), oxazepam
(Serax), paroxetine (Paxil), perphanazine (Trilafon), pimozide (Orap), prazepam (Centrax), prochlorperazine (Compazine), quetiapine
(Seroquel), risperidone (Risperdal), sertraline (Zoloft), temazepam (Restoril), thioridazine (Mellaril), thiothixene (Navane), trazodone
(Desyrel), triazolam (Halcion), trifluoperazine (Stelazine), trimipramine (Surmontil), venlaxafine (Effexor), zolpidem (Ambien).
Nevada
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir, azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), ganciclovir (Cytovene),
itraconazole (Sporonox), leucovorin, pyrimethamine, sulfadiazine, TMP/SMX (Septra). Other OIs- ciprofloxacin (Cipro), clindamycin
(Cleocin), clotrimazole (Mycelex), dapsone, erythropoietin, ethambutol (Myambutol), GCSF (Neupogen), nystatin (Nilstat),
paromomycin (Humatin). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Hyperlipidemia- pravastatin (Pravachol). Wasting- dronabinol (Marinol), megestrol acetate (Megace), oxandrolone (Oxandrin),
testosterone.
ALL OTHERS
amitriptyline (Elavil), diphenoxylate/atropine (Lomotil), gabapentin (Neurontin), loperamide (Imodium), ondansetron (Zofran),
pancreatic enzymes (Ultrase), prochlorperazine (Compazine), trazadone (Desyrel).

New Hampshire
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), famciclovir (Famvir), fluconazole (Diflucan),
ganciclovir (Cytovene), isoniazid (Rifater), itraconazole (Sporonox), leucovorin (Wellcovorin), pyrazinamide, pyrimethamine
(Daraprim), rifampim (Rimactane, Rifadin), TMP/SMX (Bactrim, Septra). Other OIs- atovaquone (Mepron), ciprofloxacin (Cipro),
clindamycin (Cleocin), clotrimazole (Lotrimin, Mycelex), dapsone, ethambutol (Myambutol), ketoconazole (Nizoral), metronidazole
(Flagyl), nystatin (Mycostatin), pentamidine (Pentam), primaquine, rifabutin (Mycobutin), trimethoprim (Proloprim, Trimpex),
valacyclovir (Valtrex), valganciclovir (Valcyte). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Hyperlipidemia- atorvastatin (Lipitor), fenofibrate (Tricor), gemfibrozil (Lopid), pravastatin (Pravachol), simvastatin (Zocor).
Wasting- dronabinol (Marinol), megestrol acetate (Megace), oxandrolone (Oxandrin), testosterone (Testoderm).
ALL OTHERS
bupropion (Wellbutrin, Zyban), cephalexin (Keflex), cefuroxime (Ceftin), chloroquine (Aralen), citalopram (Celexa), clonazepam
(Klonopin), dicloxacillin, diphenoxylate/atropine (Lomotil AD), divalproex (Depakote), famotidine (Pepcid), fluoxetine (Prozac),
gabapentin (Neurontin), granisetron (Kytril), lansoprazole (Prevacid), levofloxacin (Levaquin), lorazepam (Ativan), mirtazapine
(Remeron), nefazodone (Serazone), olanzapine (Zyprexa), omeprazole (Prilosec), ondansetron (Zofran), oxazepam (Serax),
panrelipaxe (Ultrase), paroxetine (Paxil), penicillin (V-Cillin K), ranitidine (Zantac), risperidone (Risperdal), sertraline (Zoloft),
terbinafine (Lamisil), venlafaxine (Effexor).
New Jersey
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporonox), leucovorin,
pyrazinamide, pyrimethamine (Daraprim, Fansidar), rifampim, sulfadiazine, TMP/SMX (Bactrim). Hepatitis C- all FDA approved drugs.
ALL OTHERS
Open Formulary. all FDA approved drugs are covered.
Specific exclusions: cosmetics, fertility drugs, less than effective drugs, over the counter mediations. impotence treatments limited to
four times a year.

New Mexico
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), famciclovir (Famvir), fluconazole (Diflucan),
foscarnet (Foscavir), ganciclovir (Cytovene), itraconazole (Sporonox), leucovorin, pyrimethamine (Daraprim), sulfadiazine, TMP/SMX
(Bactrim, Septra). Other OIs- amikacin (Amikin), amphotericin B, atovaquone (Mepron), ciprofloxacin (Cipro), clindamycin (Cleocin),
clofazimine (Lamprene), clotrimazole (Mycelex), dapsone, erythropoietin (Epogen), ethambutol (Myambutol), filgrastim (G-CSF,
Neupogen), ketoconazole (Nizoral), metronidazole (Flagyl), nystatin (Mycostatin), pentamidine (Nebupent, Pentam), primaquine,
rifabutin (Mycobutin), trimethoprim (Proloprim), valacyclovir (Valtrex), valganciclovir (Valcyte). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Diabetic- metformin (Glucophage). Hyperlipidemia- atorvastatin (Lipitor), gemfibrozil (Lopid), pravastatin (Pravachol). Wasting-
Megestrol (Megace).
ALL OTHERS
Centrum Silver, Nizoral Cream, Prenatal-S, sertraline (Zoloft), Tegrin Shampoo. contraceptives (condoms with/without nonoxynol
9, Spermicidal Foam, VCF Spermicidal Film, Depo-Provera, Norplant, Ovulation thermometer, Fertility Awareness book, charts,
videotape“All Methods” counseling pamphlet, Oral Contraceptives, Loestrin Fe, Micronor, Nordette, Ortho-Cyclen, Ortho
Novum, Triphasil)

New York
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir, azithromycin, cidofovir, clarithromycin, famciclovir, fluconazole, foscarnet, ganciclovir, isoniazid, itraconazole,
leucovorin, pyrazinamide, pyrimethamine, rifampim, rifampim in combination, sulfadiazine, TMP/SMX. Other OIs- albendazole,
amikacin, amphotericin B, atovaquone, bleomycin, capreomycin, ciprofloxacin, clindamycin, clotrimazole, cyclophosphamide, cycloserine,
cytarabine, dapsone, dexamethasone, doxorubicin, econazole nitrate, epoetin alfa, ethionamide, ethambutol, etoposide, filgrastim,
flucytosine, formivirsen, griseofulvin, immune globulin Rho (Win Rho SDF), IVIG, kanamycin, ketoconazole, liposomal doxorubicin,
liposomal daunorubicin, lomustine, miconazole, methotrexate, nystatin, ofloxacin, oprelvekin (Neumega), paclitaxel, panretin gel,
para-amino salicyclic acid, paromomycin, penciclovir, pentamidine, prednisone, primaquine, procarbazine, rifabutin, rifapentine,
sargramostim, streptomycin, sulfadoxine/pyrimethamine, sulfamethoxazole, terbinafine, terconazole, trimethoprim, triple sulfa,
valacyclovir, valgancyclovir, vinblastine, vincristine. Hepatitis C- alpha interferon, ribavirin.
TREATMENTS FOR METABOLIC DISORDERS
Cardiac- acebutolol, amiloride, amlodipine, atenolol, benazepril, bendroflumethiazide, betaxolol, bisoprolol,bumetanide, candesartan,
captopril, carteolol, carvedilol, chlorothiazide, chlorthalidone, clonidine, cyclandelate, digoxin, diltiazem, doxazosin, enalapril, felodipine,
fosinopril, furosemide,guanabenz, guanadrel, guanfacine, hydralazine, hydrochlorothiazide, hydroflumethiazide, indapamide, irbesartan,
isosorbide, isoxsuprine, isradipine, labetalol, lisinopril, losartan, methyclothiazide, methyldopa, metolazone, metoprolol, minoxidil,
moexipril, moricizine, nadolol, nicardipine, nifedipine, nisoldipine, nitroglycerin, papaverine, penbutolol, pindolol, polythiazide,
prazosin, procainamide, propranolol, quinapril, ramipril, sotalol, spironolactone, telmisartan, terazosin, tocainide, torsemide, trandolapril,
triamterene, trichlormethiazide, valsartan, verapamil. Diabetic- acarbose, acetohexamide, chlorpropamide, glimepiride, glipizide,
glyburide, insulin, metformin, miglitol, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone. Hyperlipidemiaatorvastatin,
cerivastatin, cholestyramine, clofibrate, colestipol, fenofibrate, fluvastatin, gemfibrozil, lovastatin, niacin, pravastatin,
simvastatin. Wasting- cyproheptadine, dronabinol, megestrol acetate, nandrolone, oxandrolone, testosterone, thalidomide.
ALL OTHERS
acetylcysteine, acrivastine/pseudoephedrine, albuterol, alclometasone, alpha N3, alprazolam, amcinonide, amitriptyline, amoxicillin,
amoxicillin/clavulanate, ansaid, ampicillin, apraclonidine, atropine, azatadine, azatadine/pseudoephedrine, aztreonam, bacitracin,
beclomethasone, benztropine mesylate, betamethasone dipropionate, betamethasone valerate, betaxolol, bitolterol, brimonidine,
brinzolamide, brompheniramine w/wo combinations, budesonide, bupropion, buspirone, butabarbital, butalbital combination w/wo/
codeine, carbamazepine, carbinoxamine, carbinoxamine/pseudoephedrine, carteolol, cefaclor, cefadroxil, cefazolin, cefixime, cefoxitin,
cefpodoxime, cefprozil, ceftazidime, ceftriaxone, cefuroxime, cephalexin, cephradine, cetirizine, chloral hydrate, chloramphenicol,
chlordiazepoxide w/wo clidinium, chlorhexidine, chlorpheniramine w/wo/ combinations, chlorpromazine, cimetidine, citalopram,
clemastine, clobetasol, clocortolone, clomipramine, clonazepam, clorazepate, cloxacillin, clozapine, codeine w/wo/ ASA, APAP,
cromolyn sodium, cyclopentolate, demearium, desipramine, desonide, desoximetasone, dexbrompheniramine / pseudo, dexchlorpheniramine,
dextroamphetamine sulfate, diazepam, diclofenac, dicloxacillin, diflorasone, diflunisal, diphenhydramine, diphenoxylate w/atropine
sulfate, dipivefrin, divalproex sodium, dolasetron, dorzolamide, dorzolamide w/ timolol, doxepin, doxycycline, dyphylline, ecothiopate,
epinephrine, epinephryl borate, erythromycin, erythromycin ethylsuccinate, erythromycin ethylsuccinate and sulfisoxazole acetyl,
estrogen, estrogens w/progestins, famotidine, fenoprofen, fentanyl (patch only), fexofenadine hcl/pseudo,fexofenadine, flavoxate,
flunisolide, fluoride, fluocinonide, fluorometh/sulfacetamide, fluorometholone, fluoxetine, fluphenazine,flurandrenolide, flurazepam,
flurbiprofen, fluticasone, fluvoxamine, fosfomycin tromethamine, furazolidone, gabapentin, gentamicin, granisetron, halazepam,
halcinonide, halobetasol, haloperidol, hepatitis A & B vaccines, homatropine, hydrocodone w/ ASA, APAP, hydrocortisone w/wo/
combinations, hydromorphone, hydoxyzine HCI, hydoxyzine pamoate, ibuprofen, imipenem/cilastatin, imipramine, imiquimod,
indomethacin, ipratropium, ipratropium and albuterol, ketoprofen, ketorolac, lansoprazole, latanoprost, levobunolol, levofloxacin,
levorphanol, lithium carbonate, lithium citrate, loperamide, loracarbef, loratadine, loratadine/pseudoephedrine, lorazepam, loteprednol,
loxapine, magnesium sulfate, medrysone, mesoridazine, metaproterenol, methadone, methylphenidate, metipranol, metoclopramide,
metronidazole, minocycline, mirtazapine, misoprostol, molindone, mometasone, montelukast, morphine sulfate, mupirocin, mydriatic
combinations, naphazoline w/wo combinations, naproxen, nedocromil, nefazodone, neomycin w/wo/ combinations, nitrofurantoin,
nizatidine, nortriptyline, octreotide, olanzapine, omeprazole, ondansetron, opium (tincture), oxazepam, oxtriphylline, oxybutynin,
oxycodone w/wo/ ASA, APAP, pancreatic enzymes, paregoric, paroxetine, pemoline, penicillin G, penicillin V potassium, pentobarbital,
perphenazine, phenir/ppa/phenylt./pyrilamine, phenylprop/pyril/pheniramine, phenyltolox/APAP, phenyltolox/pyril/pheniramine,
phenytoin, pilocarpine, pilocarpine w/ epinephrine, pirbuterol, piroxicam, podofilox, prazepam, prednisolone, prednicarbate, primidone,
probenecid, prochlorperazine, progestins, prometh/phenylephrine, promethazine, quetiapine fumarate, ranitidine, rimexolone,
risperidone, salmeterol, scopolamine, secobarbital, sertraline, sparfloxacin, spectinomycin, sucralfate, sulfacetamide sodium/prednisolone,
sulfasalazine, sulindac, suprofen, temazepam, terbutaline, tetracycline, theophylline, thiethylperazine, thioridazine, thiothixene,
ticarcillin/clavulanate, timolol, tobramycin, tolmetin, tolterodine, tramadol, trazodone, triamcinolone acetonide, triazolam, triamcinolone,
trifluoperazine, trimethobenzamide, trimipramine, tripelennamine, triprolidine hcl/pseudo, tromethamine, tropicamide, vancomycin,
valproic acid, venlafaxine, zafirlukast, zileuton, zolpidem.

North Carolina
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), famciclovir (Famvir), fluconazole (Diflucan),
ganciclovir (Cytovene), itraconazole (Sporonox), leucovorin, pyrimethamine (Daraprim), sulfadiazine, TMP/SMX (Bactrim, Cotrim,
Septra, Sulfatrim). Other OIs- atovaquone (Mepron), ciprofloxacin (Cipro), clindamycin (Cleocin), dapsone, ethambutol (Myambutol),
ketoconazole (Nizoral), nystatin (Mycostatin, Nilstat), paromomycin (Humatin), pentamidine (NebuPent), rifabutin (Mycobutin),
valacyclovir (Valtrex), valganciclovir (Valcyte). Hepatitis C- none.
ALL OTHERS
amitriptyline (Elavil), diphenoxylate (Lomotil), lansoprazole (Prevacid), loperamide (Imodium), nortriptyline (Pamelor), omeprazole
(Prilosec), ondansetron (Zofran), pancrelipase (Pancreas), prochlorperazine (Compazine), promethazine (Phenergan).
North Dakota
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), itraconazole (Sporonox), leucovorin (Wellcovorin), pyrimethamine
(Daraprim), sulfadiazine, TMP/SMX (Bactrim, Septra). Other OIs- albendazole (Albenza), amphotericin B (Fungizone), amoxicillin
(Amoxil), atovaquone (Mepron), ciprofloxacin (Cipro), clindamycin (Cleocin), clotrimazole (Lotrimin, Mycelex), dapsone,
erythromycin (Erythrocin, Ery-Tab, EES), erythropoietin (Epogen, EPO, Procrit), ethambutol (Myambutol), filgrastim (G-CSF,
Neupogen), ketoconazole (Nizoral), nystatin (Mycostatin), paromomycin (Humatin, Aminosidine, AMS), pentamidine (NebuPent,
Pentam, Pentacarinat), prednisone (Deltasone, Meticorten, Orasone), rifabutin (Mycobutin). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Cardiac- doxazosim mesylate (Cardura), lisinopril (Zestril). Hyperlipidemia- atorvastatin (Lipitor). Wasting- dronabinol
(Marinol), megestrol acetate (Megace).
ALL OTHERS
acetaminophen/codine (Tylenol #3), amantadine (Symmetrel), amitriptyline (Elavil), calcium acetate (PhosLo), chlor-hexidene (Peridex),
diphenoxylate w/atropine (Lomotil), fludrocortisone (Florinef), fluoxetine (Prozac), gabapentin (Neurontin), haloperidol (Haldol),
hepatitis B vaccine, influenza vaccine, loperamide (Imodium), lorazepam (Ativan), morphine (Duramorph, Oramporph, Roxanol),
morphine sulfate (MS Contin), olanzapine (Zyprexa), pantoprazole sodium (Protonix), pneumococcal vaccine, prochlorperazine
(Compazine), propoxyphene N-100 (Darvocet), ranitideine(Zantac), sertraline (Zoloft), trazodone (Desyrel), venlafaxine (Effexor),
vitamin (Nephrocap), zanamivir (Relenza).
Ohio
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), pyrimethamine
(Daraprim), TMP/SMX (Bactrim). Other OIs- clotrimazole (Mycelex), dapsone, ethambutol (Myambutol), ketoconazole (Nizoral),
nystatin (Nilstat), pentamidine (Pentam), rifabutin (Mycobutin). Hepatitis C- none.

Oklahoma
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), itraconazole
(Sporonox), TMP/SMX (Bactrim, Septra). Other OIs- dapsone, pentamidine (NebuPent, Pentam), rifabutin (Mycobutin).
Hepatitis C- none.
Oregon
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (Nydrazid, Rifamate, Rifater), itraconazole (Sporonox),
leucovorin, pyrazinamide (Rifater), pyrimethamine (Daraprim, Fansidar), rifampim (Rifamate, Rifater, Rifadin, Rimactane),
sulfadiazine, TMP/SMX (Bactrim, Cotrim, Septra). Other OIs- amikacin, atovaquone (Mepron), ciprofloxacin (Cipro), clindamycin
(Cleocin, Clinda-Derm), clotrimazole (Mycelex), cycloserine (Seromycin), dapsone, daunorubicin (DaunoXome), doxorubicin
(Adriamycin, DOXIL, Rubex), epoetin alfa (Epogen, Procrit), ethambutol (Myambutol), ethionamide (Trecator), fomivirsen sodium IV
(Vitravene), filgrastim (Neupogen), ketoconazole (Nizoral), metronidazole (Flagyl), ofloxacin (Floxin), para aminosalicyclic acid (PAS),
pentamidine (Nebupent), rifabutin (Mycobutin), streptomycin, trimetrexate glucuronate (Neutrexin), valacyclovir (Valtrex).
Hepatitis C- Interferon alfa 2a,2b (Intron A, RoferonA).
TREATMENTS FOR METABOLIC DISORDERS
Diabetic- acarbose (Precose), chlorpropamide (Diabinese), metformin HCI (Glucophage), glimepride (Amaryl), glipizide (Glucotrol),
glyburide (DiaBeta, Glynase, Micronase), insulins (all insulins). Hyperlipidemia- atorvastatin (lipitor), clofribate (Atromid),
gemfibrozil (Lopid), fluvastatin (Lescol), lovastatin (Mevacor), pravastatin (Pravachol), simvastatin (Zocor). Wasting- dronabinol
(Marinol), megestrol acetate (Megace), nandrolone decanoate (Deca-Durabolin), oxandrolone (Oxandrin), testosterone cypionate (Birilon
IM), testerone enanthate (Delatestryl), thalidomide.
ALL OTHERS
acetaminophen (various), alfentanil (Alfenta), alglucerase (Ceredase), alteplase (Activase), amitriptyline (Elavil, Etrafon, Triavil,
Limbitrol), amoxapine (Asendin), amoxicillin (Amoxil, Wymox), amoxicillin/calvulanate potassium (Augmentin), ampicillin sodium/sulbactam
sodium (Unasyn), Arco-Lase Plus, asparaginase (Elspar), aspirin (Easprin), buprenorphine (Buprenex), buproprion (Wellbutrin),
buspirone (Buspar), butalbital (Various), carbamezapine (Atretol, Tegretol, Epitol), cefazolin sodium (Ancef, Kefzol), chlordiazepoxide
(Limbitrol), choline (Trilisate), clonazepam (Klonopin), clorazepate (Tranxene, Gen-xene), codine (Various), desipramine (Norpramin),
dezocine (Dalgan), diazepam (Dizac, Balium), diclofenac (Cataflam, Voltaren), difenoxin HCI (Motofen), diflunisal (Dolobid), dihydrocodeine
(DHCplus, Synalgos), diphenoxylate HCI (Lomotil), disoium/clavulanate potassium (Timentin), doxepin (Adapin, Sinequan,
Zonalon), doxycycline calcium (Vibramycin Calcium), enoxacin (Penetrex), erythromycin (all forms),
ethosuximide (Zarontin), ethotoin (Peganone), etodolac (Lodine), felbamate (Felbatol), fenoprofen (Nalfon), fentanyl (Duragesic,
Sublimaze), fluoxetine (Prozac), fosphenytoin (Cerebyx), furazolidone (Furoxone), gabapentin (Neurontin), gentamicin (Garamycin,
G-myticin), hepatitis A vaccine, hepatitis B vaccine, h. influenza B vaccine, hydrocodone (Various), hydromorphone (Dilaudid),
ibuprofen (IBU, Motrin), imiglucerase (Cerezyme), imipramine (Tofranil), indomethacin (Indocin), influenza vaccine, ketoprofen
(Orudis, Oruvail), ketorolac (Toradol), lamotrigine (Lamictal), levofloxacin (Levaquin), levomethadyl (Orlaam), levorphanol (Levo-
Dromoran), lomefloxacin HCI (Maxaquin), loperamide HCI (Imodium), maprotiline (Ludiomil), meclizine (Antivert), mefenamic
(Ponstel), meperidine (Demerol, Mepergan), mephenytoin (Mesantoin), mephobarbital (Mebaral), methadone (Dolophine),
methotrimeprazine (Levoprome), methasuximide (Celontin), midrin, mirtazipine (Remeron), MMR (measles, mumps, rubella), morphine
(various), nabumetone (Relafen), nalbuphine (Nubain), naproxen (Anaprox, Naprelan), nefazodone (Serzone), nortriptyline (Pamelor),
octreotide acetate (Sandostatin), ondansetron HCI (Zofran), opium (Tincture), orphenadrine (Norflex, Norgesic, Mio-Rel), oxaprozin
(Daypro), oxycodone (Various), oxymorphone (Numorphan), paroxetine (Paxil), penicillin (Pen-Vee K), pegademase (Adagen), pegaspargase
(Oncaspar), pentazocine (Talacen, Talwin), pentobarbital (Nembutal), perphenazine (Etrafon,Triavil), phenacemide (Phenurone),
phenelzine (Nardil), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), piroxicam (Feldene), pneumococcal (Pneumovax), polio
vaccine, prochlorperazine (Compazine), promethazine HCI (Phenergan), propoxyphene (Darvocet, Darvon, Wygesic), protriptyline
(Vivactil), salsalate (Disalcid, Mono-Gesic, Salflex), sertraline (Zoloft), sufentanil (Sufenta), sulindac ( Clinoril), tetanus-diptheria vaccine,
ticarcillin, tolmetin (Tolectin), tramadol (Ultram), tranylcypromine (Parnate), traumeel, trazodone (Desyrel), trimethobenzamide HCI
(Tigan), trimipramine (Surmontil), trovofloxacin (Trovicin), valproic acid (Depakene), varicella vaccine, venlaxafine (Effexor).

Pennsylvania
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir, azithromycin, clarithromycin (Biaxin), fluconazole, foscarnet (Foscavir), ganciclovir, isoniazid, itraconazole,
leucovorin, pyrazinamide, pyrimethamine, rifampim, sulfadiazine, TMP/SMX (Bactrim, Septra). Other OIs- amikacin, amphotericin B,
atovaquone (Mepron), bleomycin, capreomycin, ciprofloxacin, clindamycin, clofazimine, clotrimazole, cycloserine, dapsone,
dexamethasone, doxorubicin, ethambutol, ethionamide, etoposide, flucytosine, kanamycin sulfate, ketoconazole, nystatin, ofloxacin,
paromomycin sulfate, pentamidine, prednisone, primaquine phosphate, rifabutin, sulfadoxine & pyrimethamine, terconazole,
trimetrexate glucuronate (Neutrexin), triple sulfa, vinblastine sulfate, vincristine sulfate, valacyclovir.
Hepatitis C- alpha interferon.
TREATMENTS FOR METABOLIC DISORDERS
Wasting- dronabinol (Marinol), megestrol acetate (Megace).
Puerto Rico
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), famciclovir (Famvir), fluconazole (Diflucan),
foscarnet (Foscavir), ganciclovir (Cytovene), isoniazid (INH), itraconazole (Sporanox), leucovorin, pyrazinamide (PZA), pyrimethamine
(Daraprim), rifampin (Rifadin), sulfadiazine, TMP/SMX (Septra). Other OIs- amikacin (Amikin), amphotericin B (Fungizone),
atovaquone (Mepron), capreomycin (Capastat), ciprofloxacin (Cipro), clindamycin (Cleocin), clofazimine (Lamprene), clotrimazole
(Lotrimin, Mycelex), cycloserine (Sermycin), dapsone, epoetin alfa (Procrit), ethambutol (Myambutol), ethionamide (Trecator SC),
filgrastim (Neupogen), IVIG (Gamimune-N, Gammagard), kanamycin (Kantrex), ketoconazole (Nizoral), metronidazole (Flagyl),
nystatin (Mycostatin), ofloxacin (Floxin), para aminosalicyclic acid (Paser), paromomycin (Humatin), pentamidine (NebuPent, Pentam),
rifabutin (Mycobutin), triple sulfa, valacyclovir (Valtrex). Hepatitis C- interferon alfa 2b (Intron A).
TREATMENTS FOR METABOLIC DISORDERS
Wasting- megestrol acetate (Megace),
ALL OTHERS
acetaminophen (Tylenol), albuterol (Proventil), amytriptyline (Elavil), amoxicillin (Trimox), amoxicillin/clavulanate (Augmentin),
antacids (Mylanta, Maalox), betamethasone dipropionate (Diprolene), betamethason/clotrimazole cream (Lotrisone), capsaicin (Zostrix),
cefadroxil (Duricef), ceftriaxone (Rocephin), cetirizine (Zyrtec), clindamycin vaginal cream (Cleocin), clotrimazole vaginal cream
(Gyne-Lotrimin), cold cream (generic), diphenhydramine (Benadryl), doxycycline (Vibramycin), econazole nitrate (Spetazole),
erythromycin base (PCE), flurbiprofen (Ansaid), fluocinonide (Synalar), fluoxetine (Prozac), guaifensin / oxtriphyline (Brondelate),
guaifenesin / phenylephrine (Albatussin SR, NN), hydrocortisone cream, hydroxyzine pamoate, ibuprofen (Motrin), imiquimod (Aldara),
Ionil-T shampoo, ketaconazole shampoo, Ku-Zyme (amylase, cellullase, lipase, protease), lanzoprazole (Prevacid), lidocaine HCI
(Emla Cream, Xylocaine), lindane shampoo/lotion, loperamide (Imodium), loratidine (Claritin), metronidazole vaginal cream
(Metrogel), mometasone (Elocon), Neosporin, Nutraderm lotion, penicillin G benzathine (Bicillin LA), podophyllin, pseudoephedrine /
triprolidine (Actifed), ranitidine (Zantac), sertraline HCI (Zoloft), spectomycin (Trobicin), sucralfate (Carafate), terbenafine (Lamisil),
terconazole vaginal cream (Terazol), triamicinolone (Kenalog), tricloric acid, tubercullin (Tubersol), vitamins and minerals (Albafort,
Alba-Lybe, ferrous sulfate, Folinic Acid, Iberet folic, Nervidox, Piridoxina, Tia-Doce, Unicap)

Rhode Island
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (generic).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), ganciclovir (Cytovene),
isoniazid, itraconazole (Sporonox), leucovorin (Folinic Acid), pyrimethamine, sulfadiazine, TMP/SMX (Bactrim, Septra). Other OIsatovaquone
(Mepron), ciprofloxacin (Cipro), dapsone, ethambutol (Myambutol), pentamidine (Nebupent), rifabutin (Mycobutin), valacyclovir
(Valtrex). Hepatitis C- interferon alpha (Intron A).
ALL OTHERS
amitriptyline, citalopram (Celexa), clonazepam, fentanyl patch (Duragesic), fluoxetine (Prozac), lorazepam, MS Contin (200 mg only),
gabapentin (Neurontin), olanzapine (Zyprexa), Oramorph SR, Oxycondone/r-Oxycondone, Oxycontin, paroxetine (Paxil), risperidone
(Risperdal), trazodone, sertraline (Zoloft).
South Carolina
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Apothecon), azithromycin (Zithromax), clarithromycin (Biaxin), famciclovir (Famvir), fluconazole
(Diflucan), itraconazole (Sporonox), leucovorin (Folinic Acid), pyrimethamine (Daraprim), sulfadiazine, TMP/SMX (generics Bactrim,
Septra). Other OIs- atovaquone (Mepron), clindamycin (Cleocin), clotrimazole (Mycelex), dapsone, ethambutol (Myambutol),
ketoconazole (Nizoral), nystatin (Geneva), primaquine, rifabutin (Mycobutin), valacyclovir (Valtrex). Hepatitis C- none.
South Dakota
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), famciclovir (Famvir), fluconazole (Diflucan),
itraconazole (Sporonox), leucovorin, pyrimethamine (Daraprim), TMP/SMX (Septra). Other OIs- atovaquone (Mepron), ciprofloxacin
(Cipro), clofazimine (Lamprene), clotrimazole (Mycelex), dapsone, paromomycin (Humatin), pentamidine (NebuPent), rifabutin
(Mycobutin), valacyclovir (Valtrex). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Wasting- megestrol acetate (Megace).
ALL OTHERS
acetaminophen/codine, amitriptyline (Elavil), divalproex sodium (Depakote), fentanyl (Duragesic), morphine, MS Contin, phenytoin
(Dilantin), prochlorperazine (Compazine), propoxyphene (Darvocet).

Tennessee
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), itraconazole
(Sporonox), leucovorin, pyrimethamine (Daraprim), rifampim, sulfadiazine, TMP/SMX (Bactrim). Other OIs- clindamycin, dapsone,
erythropoietin (Procrit), ethambutol (Myambutol), filgrastim (Neupogen), metronidazole (Flagyl), nystatin, paromomycin (Humatin),
pentamidine (IV, NebuPent), promethazine HCI (Phenergan), rifabutin (Mycobutin). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Wasting- megestrol acetate (Megace).
ADAP FORMULARIES
ALL OTHERS
Pediatric formulations of HIV drugs are available for the following: amprenavir (Agenerase), lamivudine (3TC, Epivir), didanosine
(ddI, Videx), zidovudine (AZT, Retrovir), ritonavir (Norvir), lopinavir/ritonavir (Kaletra), atovaquone (Mepron), megestrol acetate
(Megace).
Note: In addition, the following medicines are available through the Medical Services Fee Schedule:
amphotericin B, ceftraxione (Rocephin), cosyntropin (Cortrosyn), foscarnet (Foscavir), ganciclovir, vancomycin.
Texas
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), ganciclovir (Cytovene),
itraconazole (Sporonox), TMP/SMX (Bactrim). Other OIs- amphotericin B, atovaquone (Mepron), dapsone, ethambutol (Myambutol),
IVIG (Pediatric only), pentamidine (Nebupent), rifabutin (Mycobutin), trimethoprim.
Hepatitis C- interferon alpha (Roferon A).
TREATMENTS FOR METABOLIC DISORDERS
Wasting- megestrol acetate (Megace).
Utah
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).

Vermont
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), itraconazole (Sporonox), leucovorin (Wellcovorin), pyrimethamine (Daraprim),
sulfadiazine, TMP/SMX (Bactrim, Septra). Other OIs- amphotericin B (Fungizone), atovaquone (Mepron), ciprofloxacin (Cipro),
clindamycin (Cleocin), clotrimazole (Lotrimin, Mycelex), dapsone, doxorubicin liposomal (DOXIL), ethambutol (Myambutol),
filgrastim GCSF (Neupogen), ketoconazole (Nizoral), nystatin (Mycostatin), pentamidine (NebuPent, Pentam), primaquine, rifabutin
(Mycobutin), trimethoprim, valganciclovir (Valcyte). Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Hyperlipidemia- artovastatin (Lipitor), fluvastatin (Lescol), gemfibrozil (Lopid), lovastatin (Mevacor), pravastatin (Pravachol),
simvastatin (Zocor), Wasting- megestrol acetate (Megace).
ALL OTHERS
amitriptyline (Elavil), buproprion (Wellbutrin / SR), citalopram (Celexa), fentanyl (Duragesic), fluoxetine (Prozac), gabapentin
(Neurontin), ibuprofen (Motrin), loperamide (Imodium), morphine sulfate (MS Contin), nefazadone (Serzone), paroxetine (Paxil),
polycarbophil (Fibercon), psyllium (Metamucil), sertraline (Zoloft), trazodone (Desyrel), venlaxafine (Effexor).
Virgin Islands
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC), stavudine (d4T, Zerit), zalcitabine (ddC,
HIVID), zidovudine (AZT, Retrovir). PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir
(Viracept), ritonavir (Norvir), saquinavir (Fortovase, Invirase).
NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- azithromycin, fluconazole, TMP/SMX (Bactrim DS). Other OIs- ketoconazole cream, valacyclovir. Hepatitis C- none.
Virginia
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir, clarithromycin (Biaxin), fluconazole (Diflucan), foscarnet
(Foscavir), ganciclovir (Cytovene), itraconazole (Sporonox), leucovorin, TMP/SMX (Bactrim, Septra). Other OIs- atovaquone
(Mepron), dapsone, ethambutol (Myambutol), pentamidine, rifabutin (Mycobutin), trimethoprim. Hepatitis C- none.

Washington
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), cidofovir (Vistide), clarithromycin (Biaxin), famciclovir (Famvir),
fluconazole (Diflucan), foscarnet (Foscavir), ganciclovir (Cytovene), itraconazole (Sporonox), leucovorin, pyrimethamine (Daraprim,
Fansidar), rifampim (Rifadin), sulfadiazine (Microsulfon), TMP/SMX (Bactrim, Septra, CoTrim). Other OIs- albendazole, atovaquone
(Mepron), ciprofloxacin (Cipro), clindamycin, clofazimine (Lamprene), clotrimazole (Lotrimin, Mycelex), dapsone, ethambutol
(Myambutol), ketoconazole (Nizoral), metronidazole (Flagyl, Metrogel), miconazole, nystatin, oflaxacin, paromomycin (Humatin),
pentamidine (NebuPent), primaquine, rifabutin (Mycobutin), terconazole (Terazol), trimethoprim, valacyclovir (Valtrex), valganciclovir.
Hepatitis C- none.
TREATMENTS FOR METABOLIC DISORDERS
Diabetic- acarbose (Precose), insulin, injection kits, glucose test strips, glipizide (Glucotrol), glyburide (DiaBeta), metformin
(Glucophage), pioglitazone (Actos), repaglinide (Prandin), rosiglitazone (Avandia). Hyperlipidemia- atorvastatin (Lipitor),
cholestyramine (Questran), gemfibrozil (Lopid), lovastatin (Mevacor), niacin, pravastatin (Pravachol), simvastatin (Zocor),
Wasting- dronabinol (Marinol), megestrol acetate (Megace), testosterone.
ALL OTHERS
aciphex (Raberprazole), amoxicillin, amoxicillin/potassium (Augmentin), ampicillin, carbamazepine (Tegretol), cefixime (Suprax),
ceftriaxone, cephalexin (keflex), cimetidine, clotrimazole / betamethasone (Lotrisone cream), clozapine (Clozaril), dicloxacin, diphenoxylate
/ atropine (Lomotil), divalproex Sodium (Depakote), doxyclcline, erythromycin, estrogen (Premarin), famotidine (Pepcid),
gabapentin (Neurontin), Hep B Immune Globulin, Imiquimod cream, Immune Globulin IM (IGIM), lamotrigine (Lamictal),
lindane, lithium, loperamide (Imodium), Mediset fills, medroxyprogesterone (Depo-Provera), metoclopramide (Reglan), nexium
(Espmeprazole), nizatidine (Axid), olanzapine (Zyprexa), ondansetron (Zofran), opium, tincture of, oxcarbazepine (Trileptal),
penicillin, peridex, permethrin, phenazopyridine (Pyridin, Pyridium), podofilox (Condylox), prevacid (Lansoprazole), prilosec
(Omeprazole), prochlorperazine (Compazine), promethazine (Phenergan), protonix (Pantoprazole), ranitidine (Zantac), risperidone
(Risperdal), selenium sulfide, tetracycline, topical steroids -all drugs in the class, topiramate (Topamax), valproic acid (Depakene),
vancomycin oral, VZIG (Varicella Zoster Immune Globulin). The following classes of drugs are covered as groups. A drug’s class
is defined by the medical community and endorsed by the federal Food and Drug Administration. Analgesic - oral only (e.g.)
NSAIDs, Narcotics. Antianxiety - (e.g.)buspirone (Buspar), clonazepam (Klonopin), diazepam (Valium), hydroxyzine (Vistaril),
lorazepam (Ativan). Antidepressant - (e.g.)amitriptyline (Elavil), bupropion (Wellbutrin), citalopram (Celexa), clomipramine (Anafranil),
desipramine, doxepin, fluoxetine (Prozac), fluvoxamine (Luvox), imipramine, nefazodone (Serzone), nortriptyline, paroxetine (Paxil),
sertraline (Zoloft), trazodone, venlafaxine (Effexor).
West Virginia
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune).
OI DRUGS
PHS “A1 OI”s- azithromycin (Zithromax), TMP/SMX (Bactrim). Other OIs- clotrimazole (Mycelex), dapsone, ketoconazole (Nizoral),
nystatin (Mucostatin), pentamidine (NebuPent, Pentam). Hepatitis C- none.

Wisconsin
ADAP FORMULARIES
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), abacavir/lamivudine/zidovudine (Trizivir), didanosine (ddI, Videx, Videx EC), lamivudine (Epivir, 3TC),
lamivudine/zidovudine (Combivir), stavudine (d4T, Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir).
PIs- amprenavir (Agenerase), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir
(Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva), nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), ganciclovir (Cytovene),
itraconazole (Sporonox), leucovorin (Wellcovorin), pyrimethamine (Daraprim), sulfadiazine, TMP/SMX (Bactrim, Septra). Other OIsamphotericin
B (Fungizone), atovaquone (Mepron), clindamycin (Cleocin), dapsone, ganciclovir implant (Vitrasert),
ketoconazole (Nizoral), pentamidine (NebuPent), rifabutin (Mycobutin). Hepatitis C- none.
Wyoming
ANTIRETROVIRALS
NRTIs- abacavir (Ziagen), didanosine (ddI, Videx), lamivudine (Epivir, 3TC), lamivudine/zidovudine (Combivir), stavudine (d4T,
Zerit), tenofovir (Viread), zalcitabine (ddC, HIVID), zidovudine (AZT, Retrovir). PIs- amprenavir (Agenerase), indinavir (Crixivan),
nelfinavir (Viracept), ritonavir (Norvir), saquinavir (Fortovase, Invirase). NnRTIs- delavirdine (Rescriptor), efavirenz (Sustiva),
nevirapine (Viramune). Other- hydroxyurea (Hydrea).
OI DRUGS
PHS “A1 OI”s- acyclovir (Zovirax), azithromycin (Zithromax), clarithromycin (Biaxin), fluconazole (Diflucan), foscarnet (Foscavir),
ganciclovir (Cytovene), isoniazid, itraconazole (Sporonox), leucovorin (Wellcovorin), pyrazinamide (Terbrazid), pyrimethamine
(Fansidar), rifampim (Rifadin, Rifamate), sulfadiazine (Microsulfon), TMP/SMX (Bactrim, Septra). Other OIs- amikacin (Amikin),
amphotericin B (Fungizone), atovaquone (Mepron), bleomycin (Blenoxane), ciprofloxacin (Cipro), clindamycin (Cleocin), clofazimine
(Lamprene), clotrimazole (Lotrimin, Mycelex), dapsone, doxorubicin (Adriamycin), erythropoietin (Epogen, Procrit), ethambutol
(Myambutol), filgrastim (Neupogen), interferon n3, Beta, Gamma (Alferon N, Betaseron, Actimmune), ketoconazole (Nizoral),
metronidazole (Flagyl), nystatin, paromomycin (Humatin), pentamidine (Pentam), prednisone (Deltasone), primaquine, rifabutin
(Mycobutin), streptomycin, terconazole (Terazol), vinblastine (Velban), vincristine (Oncovin), valacyclovir (Valtrex).
Hepatitis C- interferon 2a, 2b (Roferon A, Intron A).
TREATMENTS FOR METABOLIC DISORDERS
Hyperlipidemia- atorvastatin (generic), simvastatin (generic), fenofibrate (Tricor).
Wasting- dronabinol (Marinol), megestrol acetate (Megace).
ALL OTHERS
amoxicillin,amoxicillin/clavulante (Augmentin), bupropion (Wellbutrin), carbamezapine (Tegretol), cephalexin, cefprozil (Procef, Prozef,
Cefzil), doxycycline, famotidine (Pepcid), fluoxetine (Prozac), ibuprofen (Motrin, Advil), lansoprazole (Prevacid), levofloxacin
(Levaquin), morphin sulfate (MS Contin/Roxanol), norfloxacin (Norflox), paroxetine (Paxil), penicillin, phenytoin (Dilantin), sertraline
(Zoloft), sulfacetamide, trifluridine (Viroptic), valproic acid (Depakene, Depakote).
Secondary Forumulary ( all generics) : acetaminophen combinations, alprazolam, amantadine, amitriptyline, amoxapine, aspirin
combinations, birth control pills and injection, bronfenac, buspirone, chlorpromazine, choline magnesium trisalicylate, choline
salicylate, citalopram, clozapine, clomipramine, codeine, desipramine, diazepam, diphenoxylate/altropine (generic), doxepin, etodolac,
fenoprofen, fentanyl, fluphenazine, fluvoxamine, guafenisin, haloperidol, hydromorphone, hydroxyzine ibuprofen, imipramine,
imiquimod cream (generic), indomethacin, Kao-Pectate (generic), ketoprofen, ketorolac, lidocaine viscus sol/gel, lithium, loperamide
(generic), lorazepam, loxapine, maprolitine, meclofenamate, mefenamic, meperidine,, methadone, mirtazapine, morphine, nabumetone,
naproxen, nefazodone, nortriptyline, olanzapine, omeprazole, oxaprozin, oxazepam, oxycodone, perphenazine, phenelzine, piroxicam,
prochlorperazine, promazine, propoxyphene, protriptyline, psyllium, quetipine, relenza, rimatadine, risperidone, salsalate, sertindole,
sulindac, tamiflu, thioridazine, thiothixene, tolmetin, topical corticosteroids, tranycypromine, trazodone, trifluoperazine, trimipramine,
venlaxafine.

The National Alliance of State and Territorial AIDS Directors
444 North Capitol Street, NW
Suite 339
Washington, DC 20001
(202) 434-8090 Fax: (202) 434-8092
www.nastad.org
AIDS Treatment Data Network
611 Broadway
Suite 613
New York, NY 10012-2809
(212) 260-8868 Fax: (212) 260-8869
www.atdn.org/access/adap
The Henry J. Kaiser Family Foundation
2400 Sand Hill Road
Menlo Park, CA 94025
(650) 854-9400 Fax: (650) 854-4800
Washington Office:
1450 G Street, NW
Suite 250
Washington, DC 20005
(202) 347-5270 Fax: (202) 347-5274
www.kff.org
Additional free copies of this publication (#6032)
are available on the Internet at www.atdn.org/access/adap, or at www.kff.org,
or by calling the Kaiser Family Foundation’s publication request line at (800) 656-4533.